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ABSTRACT 
The aim of this thesis was to investigate the effect of antihypertensive therapy 
on vascular function and placental markers in hypertensive disorders in 
pregnancy (HTD). We prospectively studied 208 women at the Homerton and 
University College London Hospitals. Vascular and serum markers were 
measured in 80 with HTD [51 pre-eclampsia (PE), 29 gestational hypertension 
(GH)] and 80 normotensive controls. The same markers were measured in 
placental samples from another 48 women (14 PE, 10 GH, 24 controls). 
Pulse wave analysis indices [augmentation pressure (AP) and augmentation 
index at heart rate 75/minute (Aix-75)], serum and placental concentrations of 
soluble fms-like tyrosine-kinase-1 (sFlt-1), soluble endoglin (sEng), placental 
growth factor (PIGF), vascular endothelial growth factor (VEGF), inhibin A, 
activin A, and uterine artery Doppler were measured before, and 24-48 hours 
after, initiating antihypertensive therapy. The three study groups were 
compared using ANOVA multiple comparisons with Bonferroni post hoc 
testing. Marker levels before and after antihypertensives were compared 
using paired t-test. 
In both pre-eclampsia (P<0.0001) and gestational hypertension 
(P<0.05), serum sFlt-1 was increased and PIGF reduced (P<0.001) compared 
to controls. Serum sEng levels were also increased in pre-eclampsia. 
Placental sFlt-1 and sEng were significantly higher (P<0.0001), and PIGF 
lower (P = 0.008), in pre-eclampsia compared to controls and gestational 
hypertension. Antihypertensive therapy was associated with a significant fall 
in serum and placental sFlt-1 and sEng in pre-eclampsia only (P<0.05). In 
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pre-eclampsia, but not gestational hypertension, treatment was associated 
with significantly (P< 0.05) lower serum and placental inhibin A and activin A. 
In women with pre-eclampsia or gestational hypertension, both AP (P<0.0001 
and P<0.05) and Aix-75 (P<0.0001 and P<0.001) were significantly higher 
than controls. Antihypertensive therapy resulted in a significant fall in both AP 
and Aix-75 in pre-eclampsia only (P<0.0001). 
Anti hypertensive drugs may have an effect on the pathophysiology of 
pre-eclampsia other than their known anti hypertensive action. 
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FIGURE LEGENDS 
Figure 1.1. The inhibin/activin 'superfamily' of the transforming growth factor 
ß family. 
Figure 1.2. Concentration of inhibin A throughout pregnancy. 
Figure 1.3. Concentration of activin A throughout pregnancy. 
Figure 1.4. The aortic waveform. The first systolic peak (P1) is the maximum 
pressure created by the advancing pressure wave. The second systolic peak 
(P2) is a composite of the advancing and reflected waveforms. Augmentation 
pressure (AP) is calculated as P2 - P1 (OP). Augmentation index (Aix) is AP 
expressed as a percentage of aortic pulse pressure (PP). 
Figure 1.5. The radial artery waveform is measured using a tonometer. 
Figure 1.6. Schematic diagram of a tonometer in use. The artery is gently 
compressed against the underlying bone and tissue. 
Figure 1.7. A radial artery waveform (left) and the corresponding aortic 
waveform (right): (a) normotensive woman and (b) hypertensive patient. 
Figure 1.8. This figure shows the difference in the aortic waveform between 
the low arterial stiffness situation and the high arterial stiffness situation. 
Figure 1.9. Uterine artery Doppler waveform: A. Measurement of the uterine 
artery waveform. B. Normal uterine artery waveform at 24 weeks' gestation. 
C. Uterine artery waveform showing notching and the point at which end 
diastolic flow (EDF) is measured. 
Figure 2.1. Schematic representation of a sandwich ELISA assay. 
Figure 2.2. Schematic representation of the inhibin A ELISA. 
Figure 2.3. Schematic representation of the activin A ELISA: 
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Figure 2.4. Dilution curves for placental samples for (a) sFlt-1, (b) soluble 
endoglin, (c) PIGF and (d) VEGF. Standard curves were obtained using the 
respective standards in the ELISA. 
Figure 3.1. Flow diagrams of women recruited to the serum (a) and placental 
(b) arms of the study respectively. 
Figure 3.2. Mean serum sFlt-1 (a), PIGF (b) and sEng (c) concentrations in 
normotensive women (controls), women with pre-eclampsia and women with 
gestational hypertension according to gestational age (GA) interval. Levels 
before and after a-methyldopa therapy are shown for women with pre- 
eclampsia and women with gestational hypertension. 
Figure 3.3. Mean maternal serum concentrations of sFlt-1 (a), PIGF (b) and 
soluble endoglin (c) in women with early onset and late onset pre-eclampsia, 
and in women with mild and severe pre-eclampsia. 
Figure 3.4. Concentrations of sFlt-1(a), PIGF (b), soluble endoglin (c) and 
VEGF (d) (expressed per mg protein) in placental tissue from normotensive 
(controls), pre-eclampsia (PE), and gestational hypertension (GH) 
pregnancies. 
Figure 3.5. Mean serum inhibin A (a) and activin A (b) concentrations in 
normotensives (controls), women with pre-eclampsia and women with 
gestational hypertension according to gestational age interval. Levels before 
and after a-methyldopa therapy are shown for women with pre-eclampsia and 
women with gestational hypertension. 
Figure 3.6. Concentrations of inhibin A (a) and activin A (b) (expressed per 
mg protein) in placental tissue from normotensive (controls), pre-eclampsia 
(PE) and gestational hypertension (GH) pregnancies. 
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Figure 3.7. Augmentation pressure (AP) (a) and augmentation index at heart 
rate 75/min (AIx-75) (b) measurements in normotensives (controls), women 
with pre-eclampsia and women with gestational hypertension according to 
gestational age interval. Measurements before and after alpha methyldopa 
therapy are shown for women with pre-eclampsia and women with gestational 
hypertension. 
Figure 3.8. Augmentation pressure (AP) (a) and augmentation index at heart 
rate 75/min (Alx-75) (b) measurements in women with early onset and late 
onset pre-eclampsia (PE), and in women with mild and severe pre-eclampsia. 
Figure 3.9. Uterine artery Doppler mean Pulsatility Index before and after 
antihypertensive therapy in women with pre-eclampsia or gestational 
hypertension, and in normotensive controls, stratified according to gestation. 
Figure 3.10. Uterine artery Doppler mean Resistance Index before and after 
antihypertensive therapy in women with pre-eclampsia or gestational 
hypertension, and in normotensive controls, stratified according to gestation. 
Figure 3.11. Uterine artery Doppler mean Pulsatility Index in women with 
early compared with late onset, and severe compared with mild pre- 
eclampsia. 
Figure 3.12. Uterine artery Doppler mean Resistance Index in women with 
early compared with late onset, and severe compared with mild pre- 
eclampsia. 
Figure 3.13. Pulse wave analysis parameters according to gestation. Scatter 
plots of (a) augmentation pressure (AP), and (b) augmentation index at heart 
rate of 75/min (Aix-75) according to the gestational age in days (n = 541). 
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Figure 3.14. Monthly changes in augmentation index at heart rate of 75/min, 
central and peripheral blood pressure. 
Figure 3.15. Longitudinal changes in pulse wave analysis parameters. 
Longitudinal data for the 45 women who had measurements taken at 12+0- 
12+6 weeks, 23+0-23+6 weeks, and 32+0-32+6 weeks of gestation: (a) 
augmentation pressure (AP), and (b) augmentation index at heart rate 75 
beats per minute (Aix-75). 
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TABLE LEGENDS 
Table 3.1. Baseline characteristics of the study groups in whom serum levels 
of markers, pulse wave analysis and uterine artery Doppler were measured, 
according to gestational age at recruitment. 
Table 3.2. Placental concentrations of sFlt-1, PIGF, sEng and VEGF 
(expressed per mg protein) in normotensive controls, pre-eclampsia and 
gestational hypertension, grouped according to whether they received 
antihypertensive therapy or not. 
Table 3.3. Placental concentrations of inhibin A and activin A (expressed per 
mg protein) in women with pre-eclampsia, women with gestational 
hypertension and controls. Women with pre-eclampsia or gestational 
hypertension are grouped according to whether they received 
antihypertensive therapy or not. 
Table 3.4. Heart rate, brachial and central haemodynamic measurements 
prior to anti hypertensive therapy in women with pre-eclampsia, women with 
gestational hypertension and matched controls. 
Table 3.5. Brachial and central haemodynamic measurements in women with 
pre-eclampsia and women with gestational hypertension. Measurements 
before and after alpha methyldopa therapy are compared. 
Table 3.6. Baseline characteristics of pregnant and non-pregnant women. 




AN Augmentation index 
Aix-75 Augmentation index at heart rate of 75 beats 
per minute 
ANOVA Analysis of variance 
AP Augmentation pressure 
BMI Body mass index 
BP Blood pressure 
BSA Bovine serum albumin 
ELISA Enzyme linked immuno-sorbent assay 
FGR Fetal growth restriction 
FSH Follicle stimulating hormone 
GA Gestational age 
GH Gestational hypertension 
GnRH Gonadotrophin releasing hormone 
HCG Human chorionic gonadotrophin 
HELLP syndrome Haemolysis, elevated liver enzymes, low 
platelets 
OD Optical density 
PAPP-A Pregnancy associated plasma protein A 
PBS Phosphate buffered saline 
PE Pre-eclampsia 
PI Pulsatility index 
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PIGF Placental growth factor 
PP Pulse pressure 
PP13 Placental protein 13 
PWA Pulse wave analysis 
QC Quality control 
RI Resistance index 
SD Standard deviation 
SDS Sodium dodecyl sulphate 
sEng Soluble endoglin 
sFlt-1 Soluble serum fms-like tyrosine kinase-1 
TGF Transforming growth factor 
UE3 Unconjugated estriol 
VEGF Vascular endothelial growth factor 
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Pre-eclampsia is a condition found only in human pregnancy. Its 
pathophysiology is still incompletely understood, so it has typically been defined 
as a triad of presenting symptoms and signs, namely hypertension, proteinuria, 
and oedema. In this thesis, the definition used is that of the International 
Society for the Study of the Hypertension in Pregnancy (ISSHP). This defines 
pre-eclampsia as "Two recordings of diastolic blood pressure z 90 mm Hg, at 
least four hours apart; or one recording of diastolic BP z 120 mm Hg, in a 
previously normotensive woman; and urine protein excretion z 300 mg in 24 
hours, or two readings of ++ or more on dipstick analysis of a midstream or 
catheter specimen of urine, if no 24 hour collection was available". ' 
1.1.2 Incidence 
Pre-eclampsia occurs in 2-8% of all pregnancies and is a leading cause of 
maternal mortality and morbid ity. 24 It is also responsible for considerable 
perinatal mortality and morbidity, as a result of both placental insufficiency and 
iatrogenic prematurity. Furthermore, pre-eclampsia carries long-term health 
implications for both mother and baby. Fetuses who suffered from intrauterine 
20 
growth restriction are at increased risk of hypertension and cardiovascular 
diseases later in life. 5"7A recent meta-analysis has shown that women who 
suffer pre-eclampsia are at increased risk later in life of ischaemic heart disease 
(RR 2.16; 95% Cl 1.86 to 2.52), hypertension (RR 3.7; 95% Cl 2.7 to 5.05), 
stroke (RR 1.81; 95% Cl 1.45 to 2.27) and venous thromboembolism (RR 1.79; 
95% Cl 1.37 to 2.33). 8 It is not known if this increased risk is a result of pre- 
eclampsia, or if factors predisposing women to pre-eclampsia also put them at 
increased risk of later cardiovascular disease. The only definitive treatment for 
pre-eclampsia is delivery of the fetus and placenta, regardless of the gestation. 
As a result, 15% of preterm births are secondary to early delivery for pre- 
eclampsia. 9 
1.1.3 Aetiology 
Despite huge investment in terms of time, effort and money, the precise 
aetiology of pre-eclampsia has yet to be fully understood. The condition was 
formerly known as `Toxaemia of pregnancy' because it was thought to result 
from a circulating toxin of fetal origin. Although a century later this idea of a 
circulating 'toxin' remains, it now seems certain that the source is the placenta 
rather than the fetus. 10-14 It is now widely accepted that abnormal trophoblastic 
invasion of maternal spiral arteries leads to placental ischaemia. 15"2' A placental 
factor is released into the maternal circulation where it has widespread effects 
on vascular endothelium, leading to the maternal syndrome of pre- 
eclampsia. 22-26 In addition, placental ischaemia may lead to intrauterine fetal 
growth restriction (FGR). As a result of endothelial damage, the maternal 
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syndrome can involve almost every major system of the body, particularly the 
brain, kidneys, liver and coagulation system. 
1.1.4 The genetics of pre-eclampsia 
The genetic aspects of pre-eclampsia are complex. 27-31 Women born after a 
pre-eclamptic pregnancy have double the risk of pre-eclampsia in their first 
pregnancy compared with women born of normotensive pregnancies (OR 2.2, 
95% Cl 2.0-2.4). 32 For men born after a pre-eclamptic pregnancy, the risk of 
pre-eclampsia in their partner's first pregnancy is also moderately increased, 
compared with men born after a pregnancy not complicated by pre-eclampsia 
(OR 1.5,95% Cl 1.3-1.7). Women and men born after pre-eclamptic 
pregnancies are also more likely to trigger severe pre-eclampsia in their own 
(or their partner's) pregnancy (OR 3.0,95% Cl 2.4-3.7 for mothers; and 1.9, 
1.4-2.5 for fathers). 
It seems likely that all these data are explained by the concept of gene 
transmission through both males and females. It is likely that some genes 
confer susceptibility to the development of pre-eclampsia in women, while 
others (transmitted to the fetus) are more likely to trigger pre-eclampsia in the 
mother. A man born of a pre-eclamptic pregnancy is more likely to possess, 
and therefore pass on to any fetus he fathers, genes which may trigger pre- 
eclampsia in the mother. Similarly, a woman born of a pre-eclamptic 
pregnancy may pass on these same pre-eclampsia triggering genes to her 
own fetus, thus making her more likely to develop pre-eclampsia during her 
own pregnancy. In addition, however, this mother may also have inherited 
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from her own mother a gene which makes her more susceptible to developing 
pre-eclampsia. Thus, women born of pre-eclamptic pregnancies themselves 
appear to be at the highest risk as they have both maternal and fetal 
predispositions. 32 
1.1.5 Immunological Factors 
It seems certain that a failure of adequate trophoblast invasion of maternal 
spiral arteries in early pregnancy eventually leads to pre-eclampsia. However, it 
is far from clear what causes this failure. Some evidence suggests that it is a 
failure of the maternal immune system to 'tolerate' fetal antigens derived from 
its father. 33-35 Pregnancies associated with a greater trophoblast mass, e. g. 
multiple pregnancy, molar pregnancy, hydropic placenta, are associated with an 
increased risk of pre-eclampsia. 36 
Pre-eclampsia tends to be most severe in first pregnancies. 37 The 
maternal exposure to paternally derived fetal antigens which occurs during the 
first pregnancy may facilitate future tolerance of these genes. As a result, the 
prevalence (and severity) of pre-eclampsia tends to be less in subsequent 
pregnancies with the same partner. There is ample epidemiological evidence 
that prior exposure to paternal antigens protects against pre-eclampsia. 36,38 
Furthermore, women becoming pregnant using donor embryos are at even 
higher risk of pre-eclampsia, presumably because the entire fetal genome is 
foreign. 39 Consistent with this theory is the observation that if women without 
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pre-eclampsia in their first pregnancy change partners for a subsequent 
pregnancy, there is a 30% increase in the risk of pre-eclampsia. 40 
1.1.5 The role of the placenta in the maternal syndrome 
Over twenty years ago, Rodgers and colleagues22 performed a series of 
elegant studies which supported the hypothesis that the hypoxic placenta 
released a factor or factors which circulated in the maternal circulation, and 
which ultimately led to endothelial cell damage. They showed that serum from 
women with pre-eclampsia was cytotoxic to cultured Human Umbilical Vein 
Endothelial Cells (HUVECs) when compared with control serum from 
normotensive pregnant women. They also showed that this cytotoxic effect 
declined rapidly when they used serum from pre-eclamptic women taken 24, 
then 48 hours after delivery. This suggested that the putative circulating 
factor(s) had a short half-life and was a product of the placenta (or fetus). The 
cytotoxic effect persisted when a mixture of sera from normal and pre-eclamptic 
women was used, suggesting that the effect was due to an active circulating 
factor, as opposed to a relative deficiency of a protective factor. 
The authors suggested that these factors caused gross morphological 
injury and cell death. However, more recent work 23,24 suggests that the 
circulating factor(s) cause an alteration in endothelial cell function (as opposed 
to morphology). These studies show that, even in the presence of pre-eclamptic 
serum, endothelial cells proliferate, adhere, and spread normally. Moreover, 
endothelial cells continue to grow well in pre-eclamptic serum, and any 
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metabolic changes can be reversed by replacing the pre-eclamptic serum with 
standard culture medium. 25 
Other investigators have confirmed that it is a property of plasma from pre- 
eclamptic women, as opposed to any intrinsic abnormality of the endothelium or 
vessel wall, which leads to the endothelial dysfunction. Ashworth et a/ 26 
incubated vessels isolated from normal pregnant women with plasma from 
women with pre-eclampsia. Using an isometric technique, they demonstrated 
an alteration in the endothelium dependent responses, such as the response to 
bradykinin, was markedly impaired. These blood vessels from normotensive 
pregnant women, in the presence of pre-eclamptic plasma, mimicked the 
behaviour of vessels isolated from women with pre-eclampsia. 
1.1.6 Oxidative stress 
Oxidative stress is a pathological state implicated in the aetiology of many 
disorders including atherosclerosis, in which pro-oxidants dominate over 
antioxidants. Recent evidence supports the hypothesis that abnormal 
placental perfusion (leading to hypoxia or hypoxia/reperfusion) results in the 
generation of reactive oxygen species 41 capable of damaging cell 
membranes, proteins and DNA. 2-x6 Plasma levels of various antioxidants are 
lower in pre-eclamptic women compared with normotensive pregnant women; 
these include ascorbic acid, alpha-tocopherol and beta-carotene. 47-51 There 
is some evidence that increased levels of plasma endothelin-1 (ET-1) in 
women with pre-eclampsia may cause oxidative stress in the placenta. 52 
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Increased superoxide generation caused by activation of NADPH oxidase is 
another possible cause of oxidative stress in the placenta in pre-eclampsia. 53 
In normal pregnancy, the onset of maternal blood flow into the placenta 
at around 10-12 weeks' gestation leads to an increase in oxygen tension. 54 
Probably in response to this rise, there is a parallel rise in the levels of several 
antioxidants in the placenta. It is postulated M that a relative lack of this 
antioxidant activity could result in oxidative stress to the trophoblast causing 
trophoblastic degeneration. This in turn could contribute to impaired 
trophoblastic invasion of the spiral arteries. In other words, oxidative stress 
may play an important role early in the pathophysiology of pre-eclampsia. 
All of this evidence suggested a potential role for antioxidants in the 
prevention of pre-eclampsia. Chappell and colleagues 55 carried out a 
prospective randomised placebo-controlled trial to examine the effects of 
vitamin C and E supplementation for women at increased risk of pre- 
eclampsia. They found a significant decrease in plasma markers of vascular 
endothelial cell activation and placental insufficiency. They also found a 
reduction in the occurrence of pre-eclampsia in the treated groups. As a result 
of this initial trial, a large multi-centre randomised trial, the Vitamins in 
Pregnancy Trial (VIP), was undertaken. Unfortunately, this failed to show any 
beneficial effects of vitamin C and E supplementation in these women. 56 
Moreover, the VIP study found an increased incidence of low birthweight 
babies (< 2.5 kg) in the women taking vitamin supplements. Clearly these 
results were disappointing. 
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1.1.7 Trophoblast microparticles 
The placenta is constantly growing but at the same time there is an ongoing 
process of apoptosis which leads to the release of syncytiotrophoblast 
microparticles into the maternal circulation. These microparticles are found in 
maternal blood in normal pregnancy, but found in significantly higher 
concentrations in the circulation of women with pre-eclampsia. 57 These 
microparticles can activate neutrophils and contribute to the systemic 
inflammatory response which characterises pre-eclampsia. 57 
1.1.8 Endothelial dysfunction in pre-eclampsia 
The vascular endothelium is not merely an inert layer lining the vasculature 
but plays an active role in mediating acetylcholine-induced relaxation, 58 
maintaining thrombo-resistance and participating in the inflammatory 
response. 59 The characteristic renal lesion known as Glomerular 
Endotheliosis, first described by Spargo in 1959,60 is found in up to 80% 
women with pre-eclampsia, but disappears completely after delivery. It 
consists of glomerular capillary cells engorged with intracellular inclusions. 
This type of lesion is not found in any other form of hypertension, suggesting 
that it is unlikely to be a result of hypertension or hypoperfusion per se; rather, 
it is likely to result from the specific endothelial damage found in pre- 
eclampsia. 
Many studies have described the hypercoagulability associated with pre- 
eclampsia. 61-65 Increased levels of fibronectin, factor VIII antigen, von 
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Willebrand's factor, tissue plasminogen activator 61,66 and circulating 
endothelin-1 62,63 have been found in the plasma of women with pre- 
eclampsia. In addition, a reduction in platelet count 64 and an increase in the 
levels of plasma ß-thromboglobulin 65 have also been described; these 
changes pre-date the clinical symptoms of the disease by several weeks. 
There is a wealth of evidence that vascular sensitivity to pressor agents 
such as angiotensin II and noradrenaline is significantly reduced in 
normotensive pregnant women . 
67 9 Women with pre-eclampsia demonstrate 
increased sensitivity to these pressor agents (similar in fact to non-pregnant 
women). A longitudinal study found that women destined to develop pre- 
eclampsia had increased sensitivity to infused angiotensin II from as early as 
18 weeks of gestation. 67 Another study 68 confirmed this finding, showing that 
the responsiveness of vessels from pre-eclamptic women and non-pregnant 
women were similar. A similar increase in sensitivity to KCI or vasopressin in 
the omental arteries of pre-eclamptic women has also been described. 70 
A decreased response to pressor agents in normotensive pregnancy has 
also been demonstrated in animal models. Furthermore, removal of the 
endothelium has no significant effect on this reduction in response, 
suggesting that these changes seen in pregnancy may be neurologically 
mediated. " 
While the responsiveness of pre-eclamptic small vessels to pressor 
agents is increased, their relaxation in response to relaxing agents is 
impaired. This has been demonstrated for acetylcholine, 72 bradykinin 73 and 
acetylcholine antihistamine. 74 This effect has been shown in subcutaneous 
resistance arteries, 72-74 omental arteries70 and small myometrial arteries. 26 
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1.1.9 Nitric Oxide in normal pregnancy and pre-eclampsia 
The role of Nitric Oxide in the vascular changes in normal pregnancy 
and pre-eclampsia is debated. Nitric Oxide (NO) is synthesized from L- 
arginine in the reaction catalyzed by the enzyme Nitric Oxide Synthase 
(NOS), a reaction which requires at least four co-factors. There are at 
least three isoforms of NOS; endothelial (eNOS) and neuronal (nNOS) 
are the two constitutive forms and they are activated by an influx of 
calcium into cells. The third isoform, inducible NOS (iNOS), is 
functionally independent of calcium. iNOS is produced in response to 
immunological stimuli and is expressed in a wide variety of cells 
including macrophages, neutrophils and mast cells. 75 
Animal studies suggest that maternal vasodilation in normal 
pregnancy is mediated at least in part by increased nitric oxide 
synthesis. 76,77 However, the situation is not as clear in human 
pregnancy. Some investigators 76,77 found increased serum 
concentrations of nitrite (a stable end product of NO metabolism) in 
normotensive pregnant women compared with non-pregnant women. 
In contrast, other investigators have found no difference in plasma or 
urinary nitrate (the second stable end product of NO metabolism) or in 
exhaled NO in normal pregnancy. 78"80 Studies in pre-eclamptic 
pregnancies also conflict; some report increased levels, 81-83 others 
finding decreased levels 84 and some reporting no difference. 78 These 
conflicting results are probably explained by differences in 
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methodology, dietary intake of nitrate and glomerular filtration rate 
(which is commonly reduced in pre-eclampsia). In an attempt to 
overcome these limitations, a longitudinal study 85 was performed in 
women whose dietary intake of nitrate was strictly controlled and 24- 
hour urine collection samples analysed. No increase in plasma or 
urinary nitrate or nitrite was found in normal pregnancy, but there was 
a modest reduction in urinary excretion of these two metabolites of NO 
in pre-eclampsia. 
Another possible explanation for these findings is that in normal 
pregnancy and pre-eclampsia nitric oxide production may vary in local 
vascular beds, whereas global production may not be significantly 
changed. 
There is increasing evidence that NO synthesis may be 
regulated by the production of endogenous inhibitors of nitric oxide 
synthesis such as asymmetric dimethyl arginine (ADMA). The fall in 
blood pressure in normal pregnancy is mirrored by a significant fall in 
plasma concentration of ADMA and, later in pregnancy (as blood 
pressure rises again), ADMA concentration also rises. 86 
Concentrations of ADMA are also significantly raised in pre-eclamptic 
women compared with non-pregnant or normotensive pregnant 
controls. 88 The authors of this study postulated that this excess ADMA 
might suppress NO synthesis, thus impairing NO mediated 
vasorelaxation. 
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However, it seems that the role of nitric oxide in the 
vasorelaxation of normal pregnancy may be limited. Various 
researchers studying small vessel relaxation described an endothelium 
dependent, NO independent vasorelaxation in subcutaneous arteries, 72 
omental small arteries, 70 and myometrial resistance arteries. 26 
Furthermore, impaired endothelium dependent relaxation has been 
described in vessels from women with pre-eclampsia, again 
suggesting that the role of NO is limited. 
1.1.10 Pre-eclampsia as an inflammatory state 
Normal pregnancy can be seen as an inflammatory process in which the 
endothelium plays a key role. 87 Monocytes, granulocytes and the endothelium 
are activated, 57 and there is evidence of increasing oxidative stress with 
advancing gestation. 88 All the inflammatory changes of normal pregnancy are 
exaggerated in pre-eclampsia. These include increased leucocytosis, 89 
leucocyte activation, 90 complement activation, 91 activation of the clotting 
system and platelets (as described above), increased markers of endothelial 
activation, 92 and increased circulating pro-inflammatory cytokines, including 
tumour necrosis factor-a, 93 interleukin-6,94 and interleukin-8.95 In a recent 
review, ̀ Redman and Sargent 96 argue that although the consequences of 
dysfunctional endothelium are responsible for the most striking clinical 
features of pre-eclampsia, the other components of the systemic inflammatory 
network are also involved. 
31 
1.2 VASCULAR AND PLACENTAL MARKERS 
1.2.1 Background 
The vascular endothelial growth factor (VEGF) super-family is key in 
angiogenesis. It includes VEGF-A to F, and placental growth factor (PIGF). 
All members of the VEGF family (including PIGF) share a common structure 
of eight characteristically spaced cysteine residues . 
97-99 VEGF-A is a key 
molecule in angiogenesis and vasculogenesis in a wide variety of situations 
including embryogenesis, corpus luteum formation, tumour growth and wound 
healing. 100 It mediates its responses primarily through the receptors VEGFR-1 
and VEGFR-2.97'101 It also increases blood vessel permeability and has an 
anti-apoptotic effect. ' 02-106 VEGF-A is highly expressed in the placenta, in both 
villous and extra-villous trophoblast cells. 107-110 
1.2.2 Placental Growth Factor 
Human placental growth factor (PIGF)'is structurally similar to the other 
members of the VEGF family, 111 113 and can potentiate their angiogenic 
effects. ' 14,115 PIGF is synthesized not just by cells of placental origin, but in 
many other tissues including human thyroid, brain, lung and skeletal 
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muscle. ' 16-120 Cross-sectional studies show that, in normal pregnancy, PIGF 
levels rise during the second trimester, reaching a peak in the early third 
trimester, probably reflecting growth of the placenta and the need to recruit 
and maintain an adequate placental circulation. 121 Levels then fall, reaching 
lower levels by the time of delivery. This gradual fall may be associated with 
slowly increasing placental hypoxia linked to increasing myometrial tone in the 
third trimester and, in particular, associated with uterine contractions during 
labour. 
VEGF receptor-1 (VEGFR-1) is also known as FMS-like tyrosine 
kinase 1 (Fit-1). It is found in trophoblast but also in pericytes, osteoblasts, 
monocytes, renal mesangial cells and in some haematopoietic stem 
cells. 122,123 Flt-1 is stimulated by PIGF, VEGF-B and VEGF-A. Fit-1 is up- 
regulated during angiogenesis and also by hypoxia. 
1.2.3 Soluble serum FMS-like tyrosine kinase 1(sFlt-1) 
Soluble serum FMS-like tyrosine kinase 1 (sFlt-1, also known as sVEGFR-1) 
is a splice variant of VEGFR-1 (Flt-1). sFlt-1 consists of the extracellular 
domain of Flt-1 and can bind to both VEGF and PIGF in maternal serum. In 
this way, it reduces the maternal serum concentration of free (i. e. bio-active) 
VEGF and PIGF, resulting in impaired angiogenesis and impaired endothelial 
cell proliferation; 124-127 in other words, sFIt-1 is an effective antagonist of 
VEGF and PIGF. 128-13° sFIt-1 is produced by a number of tissues including the 
placenta, yet its physiological role is as yet undefined. 131 Recently, evidence 
has emerged that sFlt-1 plays an important role in the pathophysiology of pre- 
eclampsia. Initial studies using in situ hybridisation showed that trophoblast 
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expresses sFlt-1 mRNA. 132 Soon after, it was discovered that serum from 
pregnant women contains a VEGF binding protein, later confirmed to be 
sFlt-1.126,133 Since then, several studies have confirmed that maternal serum 
sFlt-1 levels, placental sFlt-1 expression and amniotic fluid sFlt-1 levels are all 
elevated in pre-eclampsia. 124-127,134-140 
In vitro evidence 
Using the HUVEC (human umbilical vein endothelial cells) model, Maynard et 
al 134 demonstrated that the serum of women with pre-eclampsia has profound 
anti-angiogenic effects in-vitro. They also showed a similar effect when 
normotensive maternal serum with added sFlt-1 was used. Levels of 
circulating sFlt-1 similar to those observed in pre-eclampsia blocked the 
vasodilatation normally induced by VEGF or PIGF, suggesting that sFlt-1 
might oppose physiological vasorelaxation, thus contributing to the 
hypertension in pre-eclampsia. The authors showed that, in pre-eclampsia, 
excess sFlt-1 is released by the placenta into the maternal circulation where it 
binds to VEGF and PIGF, leading to widespread endothelial dysfunction and 
the maternal syndrome. 
Interestingly,. several earlier studies had shown that maternal serum 
VEGF levels are increased, while others have reported reduced levels in 
women with pre-eclampsia. 141147 On further analysis, however, it is clear that 
all the studies reporting increased VEGF levels measured total (both bound 
and unbound) VEGF, while those reporting reduced levels all used a. 
commercially available ELISA kit (R &D systems) which measures free 
(unbound and therefore bioactive) VEGF levels. This difference is pivotal in 
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interpreting the results in pre-eclampsia, when free VEGF may be reduced 
(because of sFlt-1 binding) while total VEGF may be unchanged. 
In vivo effects of sFlt-1 
In pregnant rats the administration of sFlt-1 causes a reaction similar to that of 
human pre-eclampsia including hypertension, proteinuria and glomerular 
endotheliosis. 134 Similar changes were observed in non-pregnant rats injected 
with sFlt-1, suggesting that its systemic effects do not actually require the 
presence of a fetus or placenta. These findings are all the more remarkable, 
given that pre-eclampsia is not observed in mammals other than humans. 
More recently, a case control study using blood samples from the 
Calcium for Pre-Eclampsia Prevention trial (CPEP) found that, in 
normotensive controls, sFlt-1 levels rose and PIGF levels fell only in the last 
two months of pregnancy. 135 In contrast, in women who later developed pre- 
eclampsia, these changes occurred earlier and were more pronounced. The 
rise in sFlt-1 levels can be detected around five weeks before the onset of 
clinical pre-eclampsia. PIGF levels were significantly lower in women who 
went on to develop pre-eclampsia than in controls. This difference could be 
detected as early as 13 weeks' gestation, and became more marked as the 
onset of pre-eclampsia approached. The rise in sFIt-l-levels was proportional 
to the fall in PIGF. This is consistent with the hypothesis that in pre-eclampsia 
there is increased release of sFlt-1 which binds to circulating PIGF, and 
suggests that a rise in sFIt-1 and fall in PIGF could predict pre-eclampsia. 
The work of other groups has confirmed these findings. 134 In women 
who subsequently develop pre-eclampsia, lower PIGF levels have been 
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demonstrated in the second trimester, 138,148 and even as early as the first 
trimester, although they are less marked at this stage. 121,149,150 Unfortunately, 
attempts at predicting pre-eclampsia using either first or second trimester 
serum PIGF have proved disappointing, with poor sensitivity and 
specificity. 151,152 
Interestingly, although rats given exogenous sFlt-1 developed a typical 
pre-eclamptic phenotype, none developed thrombocytopenia or frank HELLP 
syndrome (haemolysis, elevated liver enzymes and low platelets). 134 Recent 
work suggests that endoglin may play a role in HELLP syndrome (see 
below). 153,154 
1.2.4 Endoglin 
Endoglin (also known as Eng RCD105) is a trans-membrane glycoprotein 
found on cell surfaces, and highly expressed in endothelial cells and 
syn cytiotro p hob lasts. 154-156 A soluble form of endoglin, known as sEng, is 
found in serum. Evidence suggests that sEng is an N-terminal cleavage 
product of full length Eng. 154 Mutations in the gene encoding Eng are the 
underlying cause of hereditary haemorrhagic telangiectasia (HHT1). Eng 
plays a role in both cardiovascular development and subsequently vascular 
homeostasis. 157'158 
sEng and pre-eclampsia 
sEng was recently identified in the serum of pregnant women. ' 54,155 It has a 
molecular weight of 65 kDa and is derived from the placenta. In non-pregnant 
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women, serum levels of sEng are barely detectable and in normotensive 
pregnant women levels are low. 134 Placental expression of mRNA coding for 
Eng and placental concentrations of sEng are increased four-fold in women 
with pre-eclampsia compared with normotensive controls. 
154 
The concentration of serum sEng seems to be related to the severity of 
pre-eclampsia, with concentrations of sEng 3 -, 5 -, and 10-fold higher in 
individuals with mild pre-eclampsia, severe pre-eclampsia and HELLP 
syndrome, respectively, compared to gestational age matched controls. 
154 
The increase in serum sEng is proportional to the increase in serum sFlt-1 
levels, except in women with HELLP syndrome, in whom the rise in sEng is 
significantly greater than the rise in sFlt-1. Forty eight hours after delivery 
there is a 70% fall in the level of sEng compared with normal pregnant 
women, suggesting that sEng is derived mainly from the placenta. 
Mice pre-treated with adenovirus expressing sFlt-1, sEng or both 
exhibit a similar degree of increased capillary permeability in lungs and 
kidneys. 154 However, a combination of sFlt-1- and sEng-expressing 
adenovirus had an additive effect in liver, inducing significant vascular 
damage and leakage. This combination may be instrumental in the 
development of HELLP syndrome. 
In mice, the administration of sFlt-1 causes hypertension, severe 
proteinuria and renal endotheliosis. sEng leads to similar but less marked 
changes. 154 When both sFIt-1 and sEng are added, they cause severe 
hypertension, proteinuria and biochemical evidence of HELLP syndrome, as 
well as severe glomerular endotheliosis, placental infarction and fetal growth 
restriction in the mice litters. Liver histology demonstrates signs of ischaemia 
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and areas of necrosis, similar to those seen in the livers of women with 
HELLP syndrome. Interestingly, the administration of both sFlt-1 and sEng to 
non-pregnant rats led to signs of severe vascular damage. These findings 
suggest that sFlt-1 and sEng may play a significant role in the 
pathophysiology of pre-eclampsia and HELLP syndrome. 
Caution should be exercised in the interpretation of rodent experiments 
and in their extrapolation to human pregnancy. The rat has many similarities 
to humans and its short gestation and rapid development make it practical 
and affordable to study. 159 In recent years, the ability to create knockout and 
transgenic mouse strains has facilitated the study of genetically altered mice 
in an attempt to shed light on human physiology and pathology. However, 
there are significant differences between rodent and human pathophysiology. 
For example, one study paradoxically showed reduced atherosclerotic lesions 
in genetically engineered hyperinsulinaemic, type 2 diabetic mice. 16° In 
contrast to humans, rats are atricial animals, born with a poorly developed 
CNS and autocrine system; much of its maturation takes place during 
weaning. Rats that are growth restricted at birth show no evidence of adult 
obesity. 161 The rat has different lipid profiles to humans (cholesterol is carried 
mainly as HDL), and calorie/nutrient restriction diets in pregnant rats do not 
produce the same altered lipid profiles in offspring as those seen in humans 
with the metabolic syndrome. 
There are also some practical problems in assessing hypertension in 
rodents. In humans, the term 'hypertension' is defined as a specific level 
above the norm, which is associated with adverse outcomes. In rats, however, 
the term is often used to describe a statistically significant rise in blood 
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pressure above the control value. 162 This, combined with the fact that basal 
blood pressure varies widely in individual rats (particularly as the 
measurement process itself may cause stress to the animal) and in different 
strains of rat, means that it is difficult to set values which accurately define the 
term 'hypertension'. In one study, for example, systolic blood pressure 
measured in controls using tail cuff plethysmography ranged from 75 to 150 
mmHg. 163 
Evidence in humans 
Data in human pregnancy support a role for sEng and sFlt-1 in pre- 
eclampsia. 153 sEng levels in controls are stable until 33-36 weeks' gestation, 
then slowly increase every week until delivery. In women who subsequently 
developed term pre-eclampsia (>37 weeks), sEng levels increase slightly from 
25-28 weeks, then more rapidly at 33-36 weeks. In women who subsequently 
develop preterm pre-eclampsia, this rise begins earlier (17-20 weeks) and is 
steeper. Interestingly, in women who subsequently develop gestational 
hypertension, levels of sEng at 33-36 weeks' gestation were significantly 
higher than in controls, but significantly lower than in women who 
subsequently developed term pre-eclampsia. However, after the onset of the 
gestational hypertension, levels of sEng were similar to those in women who 
had term pre-eclampsia. Based on these data, the authors speculate that 
gestational hypertension is a mild form of term pre-eclampsia. Levels of sEng 
in women who subsequently developed preterm pre-eclampsia (i. e. the most 
severe form) rise above levels in matched controls, beginning 9 to 11 weeks 
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before the onset of clinical signs and symptoms; levels increase as the onset 
of pre-eclampsia approaches. 
Interestingly, serum sFlt-1 levels are lower, and PIGF higher, in smokers 
compared with non-smokers in normal pregnancy. 164,165 Given that smoking is 
associated with a reduced risk of pre-eclampsia, this protective effect might 
be mediated through the effects of nicotine on angiogenic factors. 
Levine's group tried to predict pre-eclampsia using the ratio of sFlt-1: 
PIGF at 20 weeks' gestation in women in the highest quartile compared with 
the lower three quartiles. An increase in this ratio predicted a greatly 
increased risk of preterm pre-eclampsia (adjusted OR 6.1; 95% Cl, 2.4 to 
15.4); and of pre-eclampsia with a small for gestational age infant (adjusted 
OR 8.1; 95% Cl, 2.6 to 24.8). 
In summary, sEng may potentially be used as a biomarker or predictor 
of pre-eclampsia. sEng and sFIt-1, each of which causes endothelial 
dysfunction by a different mechanism, contribute to the syndrome of pre- 
eclampsia. Acting in concert, they can cause severe pre-eclampsia and 
HELLP syndrome, and also fetal growth restriction. 
1.2.5 Inhibin and activin 
Inhibins and activins are glycoproteins belonging to the transforming growth 
factor beta (TGFß) super-family. 166 Identified in 1923 through their role as 
regulators in the hypothalamus-pituitary-gonadal axis, it was not until 1985 
that inhibin was isolated from follicular fluid. 167 The inhibin molecule effectively 
interferes with the secretion of FSH from the anterior pituitary. 168 Isolated in 
1986, activin is structurally related to inhibin but functionally antagonistic; it 
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stimulates the production and secretion of FSH from the anterior 
pituitary. 169-171 
Initially, inhibin and activin were thought to act only on the anterior 
pituitary but subsequently messenger RNAs coding for these proteins were 
identified in a wide variety of other tissues including placenta, adrenal glands, 
pituitary gland, bone marrow, kidneys, spinal cord and brain. 172 The actions of 
activins suggest that they should be considered as growth factors, which is 
one of the reasons they have been classified into the TGFß family of 
proteins. 173,174 
Structure of activin and inhibin 
Inhibins are dimers consisting of an a subunit and aß subunit, linked by a 
disulphide bond. The inhibin a- and ß-subunits are synthesized as pro- 
proteins (pro-a N-aC and pro-ß-13). 15 Two other inhibin-related a-subunit 
proteins have been identified: aN and pro-aC, which consist of the amino 
terminal segment and a disulfide-linked dimer of the pro- and carboxyl 
terminal region of the inhibin a-subunit precursor. 
There are two types of ß subunit, namely ßA and P B. Inhibin A 
consists of one a subunit and one 0A subunit; inhibin B consists of one a 
subunit and one ßB subunit (Figure 1.1). 166 Although the a subunits circulate 
as monomers, they are biologically inert; only dimeric forms of inhibin are 
biologically active. 
Activins and inhibins are products of the same precursors. Activins are 
dimers composed solely of ß subunits (Figure 1.1). There are three types of 
41 
activin: activin A, activin AB and activin B. Activin A is composed of two ßA 
subunits linked by a disulphide bond; activin AB is composed of one ßA 
subunit and one ßB subunit; activin B is composed of two ßB subunits 
(Figure 1.1). Activin A is identical to erythroid differentiation factor, previously 
isolated from a human leukaemic cell line. 176 
B., subunit precursor 
L 
A subunit precursor 












S= disulphide bond 
activin B 
Figure 1.1. The inhibin/activin 'superfamily' of the transforming growth factor 
P family. 
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Problems with measuring inhibin, activin and follistatin levels in serum 
Earlier assays for inhibin such as the Monash radio-immuno assay were 
unable to discriminate between the bioactive dimeric form of inhibin and the 
free biologically inactive a subunits. However, more recent enzyme linked 
immuno-sorbent assays (ELISA) measure inhibin A and inhibin B (as well as 
activin A and activin AB) with a very high level of specificity and sensitivity, to 
concentrations as low as 5 pg/mL. 177180 
Follistatin binds activin with high affinity and effectively neutralises the 
majority of its actions. 181,182 This binding can affect the accuracy of assays. A 
variety of methods have been employed to overcome this problem, such as 
analyte denaturation, dissociating agents or detergents, and sample 
extraction to enable the measurement of total activin or total 
foil istatin. 180,183-186 
Activin and inhibin in normal pregnancy 
In human pregnancy, inhibin A is the major circulating form of this protein. 
Inhibin B levels remain very low throughout pregnancy, in fact just above the 
limit of detection of most assays. In very early pregnancy, the concentration 
of inhibin A starts to rise from 5 weeks' gestation, reaching a peak at 8 
weeks. 175 The concentration then gradually falls from 8-16 weeks of gestation, 
remaining low throughout the second trimester. However, in the third 
trimester, levels rise rapidly by a factor of 5, reaching a peak at 36 weeks' 
gestation (Figure 1.2). 187 
Activin A concentrations remain low and stable between 8 and 24 
weeks' gestation (Figure 1.3). This is followed by a small but significant rise 
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from 24 to 28 weeks. There is a then slight plateau, followed by a steep rise 
from 34 weeks to a peak at 38-39 weeks' gestation. 188 There has been 
considerable debate about whether the primary source of inhibin A and activin 
A in pregnancy, particularly in early pregnancy, is the corpus luteum or the 
feto-placental unit. 189'190 However, there is now convincing evidence from 
studies using immuno-localisation, in situ hybridisation for mRNA, and 
immuno-histochemistry that the placenta is the primary source throughout 
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Figure 1.2. Concentration of inhibin A throughout pregnancy. 187 
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Figure 1.3. Concentration of activin A throughout pregnancy. 188 
The role of activin and inhibin in pregnancy remains uncertain. It has 
been shown that they increase placental production of gonadotrophin 
releasing hormone and progesterone, suggesting a hormonal role supporting 
pregnancy. 201 Activin A also has an immuno-modulating effect which may help 
to protect the fetus from rejection by its mother's immune system in early 
pregnancy. 202 Activin and inhibin may also play a paracrine role in early 
pregnancy recognition, i. e. acting locally within the ovary. 203 Inhibin A and 
activin A levels rise markedly close to term, suggesting that they may play a 
role in the initiation of labour. 187,204 
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Activins and inhibins in complicated pregnancy 
Established hypertensive disorders of pregnancy 
It is clear from a plethora of publications over the past decade that levels of 
inhibin A and activin A are significantly increased in women with established 
pre-eclampsia compared with normotensive controls. 205-214 Most authors 
consider this to be further evidence of trophoblastic dysfunction in pre- 
eclampsia. The concentration of pro-alpha C (a precursor of inhibins) is also 
increased in women with pre-eclampsia. 206,207,209 It has also been shown that, 
in women with pre-eclampsia, the serum concentration of activin A and inhibin 
A is proportional to the degree of proteinuria. 206 Some studies distinguished 
the different types of hypertensive disorders of pregnancy; 210'215,216 levels of 
activin A and inhibin A were significantly raised in pre-eclampsia, even higher 
in HELLP syndrome, but in chronic hypertension levels remained normal. It 
seems that activin A shows the greatest increase in concentration in pre- 
eclampsia so is potentially a good serum screening marker. 211,212 
Placental expression of the genes encoding for the inhibin a subunits 
and inhibin/activin ß subunits is increased in women with pre-eclampsia. 217 
However, the mechanism leading to this increase has not yet been defined. 
Urinary inhibin A, but not activin A, is significantly increased in women 
with pre-eclampsia. 218 There is also an increased fractional renal excretion of 
inhibin A, making it the best discriminator between women with pre-eclampsia 
and normotensive controls. 
When in-vitro trophoblast preparations are rendered hypoxic, the 
production of inhibin A and activin A falls significantly. 219,220 This is perhaps 
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not what would have been expected, given the increased serum levels in pre- 
eclampsia. These findings suggest that low oxygen tension may not be the 
direct mechanism leading to increased serum concentrations of these proteins 
in women with pre-eclampsia. 
Prediction of pre-eclampsia - second trimester 
An increased serum concentration of inhibin A in the second trimester is 
associated with an increased risk of developing pre-eclampsia later in 
pregnancy, and this increase occurs on average 22 weeks before clinical 
diagnosis of the disease. 208,221-224 Inhibin A predicts pre-eclampsia better than 
hCG; for a specificity of 90%, inhibin A predicted 49% of cases of pre- 
eclampsia, compared with 31 % predicted by hCG alone. 223 The addition of 
inhibin A to uterine artery Doppler indices improved the prediction of pre- 
eclampsia from 60% to 71 % for a false positive rate of 7%. 225 
The serum markers, which include inhibin A, used in the second 
trimester quadruple screening test for trisomy, can identify 40% of women 
who later develop pre-eclampsia with a false positive rate of 6%. 226 In 2006 
the performance of various potential markers for the prediction of pre- 
eclampsia was examined. 227 For a false positive rate of 5%, detection rates at 
22+0 to 24+6 weeks were as follows: 
Uterine artery mean PI 50% 
PAPP-A 5% 
Free ß hCG 10% 
Inhibin A 35% 
Activin A 44% 
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The best combination was uterine artery mean PI, maternal serum activin A 
and inhibin A, which had a detection rate of 75% for a false positive rate of 
5%, and a detection rate of 92% for a false positive rate of 10%. 
The current consensus is that the addition of inhibin A and activin A 
affords at best a modest improvement on current screening methods 
(primarily uterine artery Doppler indices alone). 
Prediction of pre-eclampsia - first trimester 
Several studies have found increased serum concentrations of inhibin A and 
activin A in the first trimester in women who subsequently developed pre- 
eclampsia, when compared with normotensive controls. 228,23° Using a specific 
cut-off value for inhibin A, the odds ratio for subsequent pre-eclampsia was 
4.9 (95% Cl: 1.8 to 13.3). 231 
While inhibin A, PAPP-A, PIGF and activin A appear to be the best first 
trimester serum markers for later development of pre-eclampsia, their 
predictive values are so poor that they currently cannot be considered useful 
in clinical practice. 228 
Screening for Down's syndrome 
In the mid 1990's, five studies showed that adding maternal serum inhibin A 
levels to the existing second trimester 'triple test' (AFP+ UE3+ ß hCG) 
significantly improved the detection rate for Down's syndrome. 232'236 Inhibin A 
is of particular value because its level in maternal serum changes little 
between 15 and 18 weeks of gestation. 
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In the first trimester there is no significant difference in maternal serum 
concentrations of inhibin A between pregnancies affected by Down's 
syndrome and normal controls. 235,237,238 
Small for gestational age 
No difference has been found in maternal serum levels of either activin A or 
inhibin A at the time of diagnosis of a small for gestational age fetus. 213 
However, levels of activin A early in pregnancy were slightly higher in those 
who later developed a small for gestational age fetus, suggesting the potential 
role of this marker in its prediction. 213 
One study which confirmed the increased maternal serum levels of 
inhibin A and activin A in pre-eclampsia found that the presence of fetal 
growth restriction did not significantly modify these concentrations. 239 
Preterm labour 
Several studies have shown that inhibin A and activin A levels rise markedly 
close to term. ' 87,204 This naturally led to speculation that they might also play a 
role in preterm labour. Data on this possible association are limited 240 and 
only few studies reported increased levels of activin A in the serum of women 
who subsequently went into preterm labour. 241242 
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1.2.6 Summary: serum and placental markers 
There is a wealth of publications in the medical literature describing changes 
in many different serum and placental markers in pre-eclampsia. At the time 
that our research was being initiated, the most promising were felt to be 
sFlt-1, PIGF, sEng, VEGF, inhibin A and activin A, so these were the serum 
and placental markers we chose to investigate for the purposes of this MD 
thesis. 
1.3 ARTERIAL PULSE WAVE ANALYSIS 
1.3.1 Historical Perspective 
The importance of the arterial pulse has been appreciated for many centuries; 
in 200 BC in 'The Yellow Emperor's Classic of Internal Medicine', 243 the 
following quote can be found: 'a hardening of the pulse... suggests disease of 
the kidney'. In 1872, Mohamed stated that'the pulse ranks the first among our 
guides; no surgeon can despise its counsel, no physician shut his ears to its 
appeal'. 244 The development of the sphygmograph by Marey, however, 
provided for the first time an objective method of recording and assessing the 
character of the arterial pulse at the wrist. Mohamed reported significant 
differences in the shape of the radial artery waveform occurring with age and 
the pre-albuminuric stage of Bright's disease (now thought to be untreated 
essential hypertension): 'The most constant of these indications is the 
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prolongation of the tidal wave; any one or all of the other characteristics may 
under certain conditions be absent'. 
In 1896, the mercury sphygmomanometer was invented by Riva Rocci 
and was rapidly adopted by physicians as it provided numbers which could be 
more easily assessed. Ironically, the use of sphygmomanometry - which 
provided only the peak pressure of systole and the nadir of diastole - meant 
that much of the information contained in the shape of the arterial waveform 
was lost or ignored. The resurgence of arterial pulse wave analysis has been 
stimulated by the advance in computer technology, allowing computerised 
analysis of the waveform. 245 
1.3.2 The Arterial Pulse Wave 
Arterial diameter ranges from several centimetres at the aorta to less than 
2O0µ for a typical resistance vessel. Arteries with a diameter of > 200µ are 
described as large arteries, and include the elastic arteries such as the aorta 
and muscular arteries such as the brachial and iliac. The pulse waveform 
does not simply pass down the arterial tree unchanged, but is altered 
significantly because of the elasticity of the vessel walls and reflection of the 
wave at several points. 
During systole, the left ventricle ejects blood into the large arteries 
whose elastic walls distend to accommodate it. This attenuates the height of 
the systolic peak. As pressure in the arteries begins to fall in diastole, the 
walls recoil, maintaining pressure during diastole. The net effect is to increase 
end-diastolic pressure and prolong the duration of forward blood flow. This 
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increase in end-diastolic pressure is particularly important as this is when the 
coronary arteries are perfused. Thus, elastic recoil of the large arteries 
smoothes the total waveform, reducing the height of the systolic peak but 
increasing the height of the diastolic part of the wave. 
Wave reflection is equally important. Each heartbeat generates a pulse 
wave which travels away from the heart along the arterial tree. This waveform 
is reflected from bifurcations in the arterial tree and from the junctions of the 
pre-resistance and resistance vessels. The reflected wave travels back 
towards the heart (Figure 1.4) and meets the advancing wave. Thus, the 
height of the pulse wave at any point in the arterial tree is the net combination 
of the advancing and reflected waves (Figure 1.4). Generally, the reflected 
wave reaches the aorta during diastole, boosting the height of the diastolic 
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Figure 1.4. The aortic waveform. The first systolic peak (P1) is the maximum 
pressure created by the advancing pressure wave. The second systolic peak 
(P2) is a composite of the advancing and reflected waveforms. Augmentation 
pressure (AP) is calculated as P2 - P1 (OP). Augmentation index (Aix) is AP 
expressed as a percentage of aortic pulse pressure (PP). 
Diastolic pressure and mean arterial pressure change little down the 
arterial tree (the slight fall of 2-3 mm Hg in mean arterial pressure from heart 
to peripheries is enough to maintain forward flow). However, systolic 
pressure, and therefore pulse pressure (which is systolic minus diastolic 
pressure) actually increases down the arm. This is a result of increasing 
arterial stiffness moving from heart to periphery and is due to the reflected 
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wave. As a result, resting radial systolic pressure exceeds aortic systolic 
pressure by around 10 mm Hg on average. 246 
Stiffening of the walls of large arteries is seen with aging and in 
pathological conditions such as diabetes and hypertension; these conditions 
cause damage to the elastic fibres in the wall, resulting in increased arterial 
stiffness. This increased arterial stiffness causes a rise in arterial pulse 
pressure in two ways: 
a) The buffering capacity of the large arteries (described above) is lost. This 
means that systolic pressure is higher and diastolic lower. 
b) The pulse wave travels more rapidly along the arterial tree, and the 
reflected wave travels more rapidly back towards the heart. Consequently, the 
reflected wave reaches the advancing wave earlier in systole, resulting in a 
higher (combined) peak. 
This increased pulse pressure increases cardiac afterload which in the 
long term could lead to left ventricular hypertrophy. 247 It also causes a 
reduction in coronary artery perfusion due to the fall in diastolic pressure. 
1.3.3 Assessment of Arterial Stiffness 
The simplest way of assessing arterial stiffness is by measuring the pulse 
pressure, usually in the brachial artery using a conventional 
sphygmomanometer. 248 However, peripheral pulse pressure depends on both 
arterial stiffness and cardiac output so is an inaccurate surrogate for stiffness. 
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Another limitation is that there is a difference between aortic (central) and 
peripheral (brachial) pulse pressure. It might be assumed that peripheral 
pulse pressure could be used as a surrogate for central pulse pressure. 
However, the relationship between the two is not fixed; it varies according to a 
variety of factors such as exercise and posture. 249 Given that it is central 
rather than peripheral pressure which is 'seen' by the important organs (the 
heart, brain and kidneys), brachial artery sphygmomanometry is clearly 
suboptimal. Central blood pressure can be measured using an intra-arterial 
catheter but this is an invasive technique. 
1.3.4 Analysis of the Arterial Pulse Wave 
The technique of pulse wave analysis (PWA) was developed and reported in 
1996.220 This technique involves three principal steps: 
Recording the radial artery pulse waveform using a tonometer. 
2. Applying a generalised transfer function to the radial artery waveform in 
order to derive the aortic waveform. 





Figure 1.5. The radial artery waveform is measured using a tonometer. 
A tonometer is a pencil-like probe containing a high fidelity micromanometer 
capable of accurately recording intra-arterial pressures (Figure 1.5). Originally 
developed to measure intraocular pressure, 
tonometers were subsequently adapted for measuring intravascular 
waveforms . 
250,25' The flat surface of the tonometer is gently pressed against 
the radial artery, slightly compressing the artery against the underlying bone 
and tissue (Figure 1.6). This flattens the curved surface of the artery, 
equalising circumferential pressures, and allowing accurate recording of intra- 
luminal pressure. 252'253 
The radial artery pressure waveforms are recorded electronically and an 
averaged waveform assembled by the software program (Sphygmocor®). A 
generalised transfer function is then applied to this radial artery waveform in 
order to derive the corresponding aortic waveform (Figure 1.7). 
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Applatwion tonomPtry. 
Figure 1.6. Schematic diagram of a tonometer in use. The artery is gently 
compressed against the underlying bone and tissue. 
Figure 1.4 shows a typical central aortic pressure waveform, which has two 
systolic peaks: P1 and P2. P1 is the maximum pressure generated in the 
wave advancing from the heart. The second peak (P2) is the result of the 
combination of the advancing and reflected waves. The Augmentation 
Pressure (AP) is the difference between P2 and P1, and may be positive or 
negative depending on the relative heights of the two peaks. Augmentation 
Index (AIx) is defined as the augmentation pressure expressed as a 
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Figure 1.7. A radial artery waveform (left) and the corresponding aortic 
waveform (right): (a) normotensive woman and (b) hypertensive patient. 
As described earlier, when arterial stiffness is increased, both the 
advancing and reflected waves travel faster; as a result, the reflected wave 
arrives back in the aorta at an earlier point in the advancing wave, i. e. early in 
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systole. This results in greater augmentation of the advancing wave, i. e. a 
higher P2 (Figure 1.8). As a result, augmentation pressure and augmentation 







Figure 1.8. This figure shows the difference in the aortic waveform between 
the low arterial stiffness situation and the high arterial stiffness situation. 254 
1.3.5 Relationship between Heart Rate and Augmentation Index 
Augmentation index is affected by changes in heart rate. An increase in heart 
rate shortens the duration of systole. As a result, the reflected wave reaches 
the advancing wave later in diastole than usual, resulting in a lower P2, i. e. 
reduced augmentation index. Using PWA, an elegant study 255 examined 
patients with in-dwelling cardiac pacemakers, paced at different heart rates. 
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Hypertensive 
This approach was preferable to pharmacological manipulation of heart rate 
as many of these drugs may also have effects on the vascular wall. For every 
10 beats per minute increase in heart rate, there was a 4% decrease in aortic 
wave augmentation. For this reason, augmentation index is adjusted for heart 
rate; a standardised measure of Alx-75 (augmentation index at heart rate 75 
beats per minute) is used. The Sphygmocor® software automatically 
calculates the value of Alx-75. 
1.3.6 Validation of the technique of Arterial Pulse Wave Analysis 
Validation of the technique of arterial pulse wave analysis was necessary 
primarily in three areas: 
a) Whether the technique of applanation tonometry could produce a 
consistent radial artery waveform. 
b) Whether the radial artery waveform measured by applanation tonometry 
accurately reflects the true radial artery waveform. 
c) Whether the generalised transformation function used to derive the aortic 
waveform from the recorded radial artery waveform is valid. 
Reproducibility 
Accurate tonometry requires that the artery be applanated (flattened) beneath 
the sensor. The technique of applanation tonometry is usually quick and easy 




Accuracy of applanation tonometry 
The waveform obtained from the radial artery using applanation tonometry 
has been compared with that obtained from invasive monitoring, and a close 
correlation between the two has been confirmed. 253,259 
Validation of the generalised transfer function 
In order to calculate the aortic pressure waveform, a transfer function must be 
applied to the measured radial artery waveform. It might be expected that the 
use of a generalised transfer function (i. e. one that could be used for all 
subjects) would not be appropriate. After all, vascular dimensions depend on 
body size and vascular properties vary with age, arterial pressure and 
vasoactive drugs. Use of a generalised transfer function would assume a 
constant relationship between the aortic and radial artery waveforms in all 
subjects under all conditions, which seems unlikely. 
However, results from clinical and theoretical studies consistently 
confirm that the use of a generalised transfer function produces surprisingly 
good calculations of the aortic waveform, approaching over 90% accuracy in 
most situations. 250,260-262 The explanation for this is likely to be that upper arm 
length varies little between different adults, and upper limb pulse wave 
velocity changes little with age, 250,260 with elevation of arterial pressure, 250,261 
or with the types of vasoactive therapy commonly used in clinical 
practice. 250,262 
A generalised transfer function was first derived in a study comparing 
calculated aortic pressure waveform with that measured invasively at cardiac 
catheterisation in 14 patients. 262 The generalised transfer function held true 
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for all 14 patients under various conditions, including following administration 
of sublingual glyceryl trinitrate. This generalised transfer function was 
subsequently rigorously tested in a further 20 patients at cardiac 
catheterisation at John Hopkins Hospital in the US. 246 Recordings were made 
during one or more of the following haemodynamic transient manoeuvres: 
Valsalva manoeuvre, manual compression of the upper abdomen, 
intravenous bolus of 200 mg nitro-glycerine, or balloon obstruction of inferior 
vena cava flow. The use of a generalised transfer function produced an aortic 
waveform which was remarkably similar to the measured aortic waveform, 
both in amplitude and contour, in all these situations. Using the measured 
peripheral and central waveforms, an individualised transfer function was 
calculated for each subject. Application of this individualised transfer function 
to the same radial pressure data did not significantly improve the accuracy of 
the derived aortic waveform. Thus, the authors concluded that the use of a 
generalised transfer function 'rather surprisingly works remarkably well in a 
variety of individuals in a variety of haemodynamic situations; and that 
'equally surprisingly, the use of an individualised transfer function produced 
only a very small additional improvement in the prediction of the aortic 
waveform. 
In 2004, the data from more than 400 patients used to calculate the 
original generalised transfer function were published. 263 This is the transfer 
function used in the Sphygmocor® software. Earlier (in 2001), the 
Sphygmocor® device had gained approval from the US Food and Drug 
Administration; this approval was based on the data subsequently published, 
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all of which assessed the transfer function by direct comparison with intra- 
arterial measures used as the gold standard. 263,264 
This generalised transfer function has not been specifically validated 
for pregnancy; this is because cardiac catheterisation is a rare event in 
pregnant women. However, as described above, it has been validated in non- 
pregnant subjects in a variety of circumstances relevant to pregnancy, such 
as Valsalva manoeuvre, manual compression of the upper abdomen, balloon 
obstruction of inferior vena cava flow, and during the administration of a 
variety of vasodilating treatments. 246,262 Given its remarkable consistency in a 
wide variety of subjects in a wide variety of clinical situations, it seems likely 
(although not yet proven) that the transfer function also holds true in pregnant 
women. 
1.3.7 Use of Pulse Wave Analysis in non-pregnant subjects 
Pulse Wave Analysis is used for the assessment of arterial function in patients 
with cardiovascular and renal disease, and diabetes. It has also been used for 
the assessment of vaso-active medications, particularly anti hypertensives. For 
example, a blinded comparison of atenolol and ramipril found that both drugs 
caused a similar reduction in both central and peripheral diastolic pressure. 
The fall in peripheral systolic pressure was also similar for both drugs. 
However, the fall in central systolic pressure (and hence pulse pressure) was 
significantly greater with ramipril compared with atenolol. 265 PWA showed that 
this difference was due to the greater reduction in arterial stiffness caused by 
ramipril. It is likely that this difference explains the greater long-term benefits 
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of ramipril. In the REASON study, 266,267 PWA established similar benefits of a 
perindopril-indapamide combination over atenolol. These examples suggest 
that PWA may have a potentially important role to play in the assessment of 
new and existing cardiovascular medications so that central - as well as 
peripheral - effects can be determined. 
Arterial PWA has been used to examine the effects of ageing on 
arteries. Because of the increase in arterial stiffness, aortic wave velocity 
more than doubles between ages 20 and 100 years. 250,260This effect is offset 
to a certain extent by physical fitness. 268 PWA is also used in clinical practice 
to assess patients with cardiac failure 269 and end-stage renal failure. 270 
Arterial stiffness has been shown to predict the risk of cardiovascular events 
in patients with diabetes, 271 end stage renal disease 272 and hypertension. 273 
Menstrual cycle fluctuations in arterial distensibility have been described in 
premenopausal women. 261 
Similarly, other studies have shown that vasodilator drugs such as 
glyceryl trinitrate cause a significant fall in central pressures, despite the 
relative maintenance of peripheral systolic pressure; 274,275 this suggests that 
arterial pulse wave analysis provides a more accurate assessment of the 
effect of this type of vasodilator. Beta-blockers tend to increase arterial wave 
reflection. 276 Calcium channel antagonists reduce aortic augmentation index 
(Alx) because of their vasodilator action; clearly this is a beneficial effect. 250 
PWA is increasingly being used in clinical practice in the diagnosis and 
management of patients with hypertension, cardiac failure, diabetes mellitus, 
nephropathy and angina. 27 
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1.3.8 Vascular endothelial factors and arterial stiffness 
A series of in vivo investigations using nitric oxide synthase inhibitors showed 
that basal nitric oxide production appears to regulate large artery stiffness, 
and that stiffness is reduced by exogenous nitric oxide donors and agonists 
that stimulate endothelial nitric oxide production. 278,279 This evidence suggests 
that arterial stiffness is not merely dependent on the intrinsic structure of the 
arterial wall but can be affected by local or circulating agents. 
1.3.9 Arterial Pulse Wave Analysis in pregnancy 
There are few reports in the literature of the use of arterial pulse wave 
analysis in pregnancy - the first appeared in 2004.280.282 Smith and 
colleagues281 studied a total of 53 normotensive women and 10 non-pregnant 
controls. They found that augmentation pressure and augmentation index 
were lower in pregnancy. However, none of the recruited women were studied 
in the first trimester (the earliest was 17 weeks' gestation) and only 20 women 
were studied in all three defined gestation groups (17-20 weeks; 25-28 weeks; 
and 33-36 weeks). 
In the same year, another study compared 51 normotensive pregnant 
women, 38 hypertensive pregnant women and 33 women with pre- 
eclampsia. 280 In both hypertensive and pre-eciamptic pregnancies, AN was 
significantly higher than in normotensive pregnant women. Within the pre- 
eclamptic group, there was no significant difference in haemodynamic 
parameters between those women on treatment and those not. However, the 
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numbers were small (16 versus 17) and no patient was studied both before 
and after starting anti-hypertensive medication. A single measurement was 
taken from each individual and the means of each group (normotensive, 
hypertensive and pre-eclamptic) compared. No comparison between 
individual values was made and no longitudinal studies of individual women 
were carried out (although the authors suggest that this `would be valuable'). 
In 2005, another study compared 27 women with pre-eclampsia, 33 
with gestational hypertension and 39 normotensive pregnant controls. 283 Each 
woman was studied once and no women with essential hypertension were 
included. Alx was increased in gestational hypertension but increased even 
more in women with pre-eclampsia. In the same year, a cross-sectional case 
control study compared four groups using PWA: 26 with pre-eclampsia, 26 
normotensive pregnant, 22 non-pregnant normotensive but previously pre- 
eclamptic women, and 22 non-pregnant controls. 284 All women were between 
30 and 42 weeks' gestation. Each woman was studied once with PWA and 
the means of each group compared. AN was significantly increased in pre- 
eclampsia compared with normotensive pregnancy. Interestingly, in the pre- 
eclampsia group, AN did not correlate with the degree of proteinuria. When 
non-pregnant controls were compared with the non-pregnant previously pre- 
eclamptic women, no significant differences in PWA parameters were found. 
The authors concluded that, although mean arterial pressure correlated with 
Aix in both pregnant and non-pregnant women (reflecting the fact that, by 
distending the arterial walls, elevated blood pressure per se causes functional 
stiffening of the large arteries), nevertheless pre-eclampsia was a strong 
independent determinant of Aix. This suggested that the pathological process 
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of pre-eclampsia contributes significantly to an increase in arterial stiffness 
over and above the increase caused by hypertension per se. 
Arterial PWA has been used to measure pulse wave velocity (PWV) 
between the carotid and femoral arteries in 50 normotensive women. 285 
Increased arterial stiffness leads to more rapid transit of the pulse wave, i. e. 
greater pulse wave velocity. Pulse wave velocity was found to be inversely 
proportional to birth weight centile, regardless of blood pressure. This 
suggests that increased arterial stiffness (represented by increased pulse 
wave velocity) may reflect the inadequate plasma volume expansion 
associated with fetal growth restriction. 
In conclusion, there are few studies of the use of arterial pulse wave 
analysis in normal or pathological pregnancy. There are no longitudinal 
studies, no studies of the effect of antihypertensive treatment on an individual, 
none attempting to predict pre-eclampsia and none of women with the most 
severe form (usually early onset) of pre-eclampsia. 
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1.4 DOPPLER ULTRASOUND 
1.4.1 Background 
The Doppler principle, first described by Christian Doppler in 1843, states that 
the frequency of a wave (light or sound, for example) emitted from a moving 
source was altered by the speed and direction of movement of the source 
itself. Ultrasound is simply sound which cannot be heard by the human ear 
and has a frequency above 20 000 Hz (20 kHz). The velocity (v) of sound 
waves is constant at 1540 m/s. The wavelength (k) multiplied by the 
frequency (f) equals the constant v: 
%= v/f 
In Doppler ultrasound a source directs ultrasound waves into tissue. Tissue 
reflects these waves to a greater or lesser degree, largely depending on its 
density, and the reflected sound is detected by the ultrasound probe. The 
frequency of the sound reflected by static tissue is unchanged. However, the 
frequency of ultrasound reflected by a moving particle is changed; this change 
is known as the 'frequency shift' (or the 'Doppler frequency'). The frequency 
shift depends on how fast the object is moving and whether it is moving 
towards or away from the probe. 
For pulsed wave Doppler and the majority of the colour flow imaging 
techniques, the equation which describes this relationship is: 
Doppler frequency = 2v ft Cos 6/c 
ft = the frequency of the transmitted ultrasound wave 
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v= the velocity of the blood 
0= the angle of insonation (between the beam and the direction of flow) 
c= speed of sound in tissue 
1.4.2 Blood Flow Measurement using Doppler Ultrasound 
Indices of Resistance 
Several different indices of resistance to blood flow have been derived but 
those most commonly used are the Resistance Index (RI) and Pulsatility 
Index (PI). All are calculated from a measured Doppler shift waveform. 
Pourcelot's Resistance Index 
Described in 1974, Pourcelot's Resistance Index (RI) is defined as peak 
Systolic height minus minimum Diastolic height divided by peak Systolic 
height: 
RI = (S-D) /S 
As diastolic flow falls, value of RI increases; if diastolic flow is absent, then RI 
equals one. RI values greater than one are possible, if there is negative 
diastolic flow. 
Pulsatility Index 
The Pulsatility Index (PI) is defined as peak Systolic Height minus minimum 
Diastolic Height divided by mean waveform height (N): 
PI = (S-D) /N 
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The PI has the advantage that it can describe a range of waveform shapes 
when there is no end-diastolic flow. 
In general, a low pulsatility index indicates that resistance distal to the 
point of measurement is low; high pulsatility index suggests high vascular 
resistance distal to the vessel being examined. It is important to remember 
that these indices are not an absolute measure of either upstream or 
downstream factors. For example, alterations in heart rate can change the 
shape of the waveform, leading to significant changes in the value of these 
indices. 286 
Qualitative analysis 
The waveform can be analysed for particular features, especially the 
presence or absence of an early diastolic notch (useful in uterine artery 
waveform analysis) or the presence or absence of end-diastolic flow 
(particularly useful when assessing the umbilical artery waveform). These 
features are useful measures of resistance (Figure 1.9). 
1.4.3 Doppler ultrasound characteristics in physiological and 
pathological conditions 
In non-pregnant women the uterine artery resistance (as measured by PI or 
RI) tends to be raised (compared with pregnant women) and the waveform 
has an early diastolic notch. In pregnancy, the uterine arteries gradually 
transform from a low volume, high resistance system to a high volume, low 
resistance circulation. This fall in vascular resistance in the uterine arteries 
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can be detected as early as five to seven weeks' gestation. 287,288 The initial 
increase in uterine artery flow is slow (from 77 mis per minute at five weeks to 
159 mis at ten weeks) but accelerates between 10 and 12 weeks, reaching 
665 mis per minute at 16 weeks of gestation. 289 The fall in utero-placental 
resistance continues until around 24 to 26 weeks. 290,291 
These changes can be detected by uterine artery Doppler examination 
(Figure 1.9a). The early diastolic notch usually disappears in the early second 
trimester (Figure 1.9b). This low resistance system (represented by loss of the 
early diastolic notch) is typical of pregnancy but has also been seen during 
the puerperium and after the menopause. 292,293 By 24 weeks' gestation, only 
5% of women will still show uterine artery notches in both uterine arteries. 294 
Persistence of this notch and/or raised PI or RI as gestation advances is an 
indicator of impaired uterine artery blood flow (Figure 1.9c). 295 
1.4.4 Uterine artery Doppler and pregnancy complications 
In the late 80's, several studies 296,297 found that impedance to flow in the 
uterine arteries is increased in pregnancies affected by pre-eclampsia or fetal 
growth restriction. These early findings triggered a wave of studies which 
attempted to identify women at increased risk of developing pre-eclampsia 
and/or fetal growth restriction before symptoms of clinical disease could be 
detected. 
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Figure 1.9. Uterine artery Doppler waveform: (a) Measurement of the uterine 
artery waveform; (b) Normal uterine artery waveform at 24 weeks' gestation; 
(c) Uterine artery waveform showing notching and the point at which end 
diastolic flow (EDF) is measured. 
Papageorghiou et a! 298 reviewed 15 good quality studies investigating the use 
of second trimester uterine artery Doppler to predict pre-eclampsia and fetal 
growth restriction. 225,294,299,300-309 Although conclusions are drawn from pooled 
data in this review, these studies are quite heterogeneous in several ways: 
V The earlier studies used continuous waveform Doppler with all its 
limitations; more recent studies used real time ultrasound and pulsed 
wave Doppler. 
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"" The criteria for defining abnormal Doppler waveforms vary (PI or RI 
above a certain centile, or the presence of an early diastolic notch). 
V The populations examined differed. For example, the prevalence of 
pre-eclampsia ranged from 1.4% to 5.5%. 
V The gestational age at which women were studied varied, ranging from 
16 to 24 weeks. 
V The criteria for the diagnosis of pre-eclampsia or fetal growth restriction 
differed. 
Four of these studies used a two stage screening program; the initial 
screen was between 18 and 20 weeks using continuous wave Doppler. 
Those with increased resistance had a repeat Doppler study at 24 
weeks. 
294,304,305 The results are interesting. Overall, women with increased 
uterine artery resistance in the second trimester were six times as likely to 
develop pre-eclampsia as women with normal second trimester Dopplers. 
Conversely, normal uterine artery Dopplers gave a likelihood ratio for pre- 
eclampsia of 0.5. As expected perhaps, the ability of mid-trimester Dopplers 
to predict pre-eclampsia is better for the more severe forms of the disease. 
For example, one study 309 found that an increased second trimester PI 
predicted 44% of women who later developed pre-eclampsia at any stage but 
that the sensitivities increased to 54%, 70%, 81 % and 90% for those who 
develop pre-eclampsia requiring delivery before 38,36,34 and 32 weeks of 
gestation respectively. The likelihood ratio for subsequent development of 
fetal growth restriction in women with increased uterine artery resistance in 
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the second trimester was 3.7. Again, the more severe the growth restriction, 
the better the predictive value of the test. 
First Trimester Uterine Artery Doppler 
Earlier studies showed a promising role of Doppler ultrasound examination of 
the uteroplacental circulation in the first trimester. 310 Early diastolic notching 
is present in 55% of the general pregnant population in the first trimester, 311 
which means it is of limited use at this gestation. Generally, uterine artery PI 
above the 95tl percentile has been used as the threshold. Examination of the 
uterine arteries is feasible in the first trimester; in one study the examination 
was successfully completed in 96% of women at 11 to 14 weeks' gestation. 311 
A study of 3,300 low risk women attending for routine antenatal care 
found that first trimester uterine artery PI above the 95th percentile had 27% 
sensitivity for later development of pre-eclampsia. However, sensitivity 
improved in proportion to the severity of the disease; the sensitivities for 
predicting pre-eclampsia requiring delivery before 36,34, and 32 weeks of 
gestation were 40%, 50%, and 60% respectively. Another study examined 
women at increased risk of developing pre-eclampsia based on their personal 
or family history. 312 This study found that bilateral uterine artery notching at 12 
to 14 weeks of gestation predicted pre-eclampsia with a sensitivity of 91 % but 
with poor specificity (46%). Nevertheless, the positive predictive value was 
high (23%) in this high risk population. 
In general, prediction rates for pre-eclampsia or fetal growth 
restriction are not as good in the first trimester as in the second. For a false 
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positive rate of 5%, around 40% of women requiring delivery for pre- 
eclampsia at less than 36 weeks, and 60% of those requiring delivery at less 
than 33 weeks' gestation, will be identified by first trimester Doppler. 311 
Combination of First Trimester Uterine Artery Doppler and Serum Markers 
Nicolaides et a!. 313 combined the use of serum placental protein 13 (PP13) 
with uterine artery Doppler PI, both measured in the first trimester (11+0 to 
13+6 weeks' gestation). Using a nested case control model, they matched 10 
women who subsequently developed pre-eclampsia requiring delivery before 
34 weeks' gestation with 423 unaffected women. Median PP13 was lower 
and uterine artery PI higher in women who subsequently developed pre- 
eclampsia. Using logistic regression analysis, the authors predicted that, for a 
detection rate of 90%, PP13 alone would have a false positive rate of 12%, 
uterine artery PI alone a false positive rate of 31 %, and a combination of the 
two a false positive rate of just 9%. They suggested the possibility of 
contingency screening. They calculated that if all women were first screened 
by serum PP13, with only those at highest risk (14%) undergoing Doppler 
examination, a detection rate of 90% could be achieved for an overall false 
positive rate of 6%. These findings have yet to be confirmed by larger 
prospective studies. 314 
First trimester uterine artery Doppler has also been combined with first 
trimester sFlt-1, Plasminogen Activator Inhibitor 1 (PAI1) to PAI2 ratio, and F- 
2 Isoprostane. 315 In this study, for a 5% false positive rate, first trimester 
Doppler alone predicted 25% of pre-eclampsia and 67% of severe pre- 
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eclampsia (requiring delivery before 35 weeks). None of the biochemical 
markers significantly improved the screening performance. 
1.5 ALPHA METHYLDOPA 
In UK clinical practice, alpha methyldopa is the antihypertensive drug most 
commonly used in pregnancy. Alpha methyldopa acts on a2-adrenergic 
receptors, primarily in the central nervous system, although an effect on 
peripheral a2-adrenoreceptors may also play a part. 316,317 Stimulation of pre- 
synaptic a2-adrenoreceptors in the central nervous system leads to a 
reduction of central sympathetic outflow and a reduction in blood pressure. 318 
Methyldopa crosses the placental barrier and appears in cord blood and 
breast milk. However, there is no evidence that it causes any harm to the 
fetus or neonate, and it is considered safe in pregnancy. 
319-321 Many women 
experience drowsiness for two or more days after commencing methyldopa. 
Women (10-20%) taking methyldopa will develop a positive Coomb's test. 
We investigated whether alpha methyldopa has an effect on 
haemodynamic and placental markers over and above its known 
antihypertensive action in hypertensive disorders in pregnancy. 
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1.6 SUMMARY AND AIMS 
In spite of decades of research, pre-eclampsia remains the `disease of 
theories'. The nature of the placental factor(s) which lead to the multisystem 
maternal syndrome, and its precise effect on maternal vascular structure and 
function, remain poorly understood. The importance of pro-angiogenic and 
anti-angiogenic factors, including sFltl, sEng, VEGF and PIGF, has recently 
been recognised, but their precise role in women with abnormal placentation 
is still not defined. 
Pulse wave analysis, which can assess arterial stiffness, has been 
widely investigated outside pregnancy and proved useful in the management 
of cardiovascular diseases. However, as yet there are few reported studies in 
pregnancy, and the numbers of women remain small. Normal values 
throughout pregnancy have not been established. 
Antihypertensive drugs are commonly used in women with 
hypertensive disorders of pregnancy. It is not known whether these drugs 
affect maternal serum levels of angiogenic factors or arterial stiffness, as 
measured by pulse wave analysis. If there is such an effect (and if it is 
independent of the antihypertensive effect of the drugs), this would imply an 
effect of the drug on the disease process itself, over and above its 
antihypertensive effect. 
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Therefore, the aims of the work carried out in this thesis are: 
1. To evaluate the effect of anti hypertensive therapy on angiogenic 
factors including sFlt-1, soluble endoglin, PIGF and VEGF in maternal 
serum and placenta. 
2. To investigate the effect of anti hypertensive therapy on the levels of 
inhibin A and activin A in maternal serum and placenta. 
3. To determine effect of anti hypertensive therapy on pulse wave 
analysis. 
4. To ascertain the effect of anti hypertensive therapy on uterine artery 
Doppler indices. 
5. To establish normal values for pulse wave analysis parameters 
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METHODS 
2.1 ETHICS APPROVAL 
Prior to commencing the study, ethics approval was obtained from the 
Camden & Islington Community Local Research Ethics Committee. Full 
written information in lay language describing the research project was 
provided and written consent obtained from each woman who agreed to 
participate. Each patient's General Practitioner was informed of her 
participation in the study. 
2.2 SUBJECTS 
2.2.1 Setting 
Participants were recruited between January 2006 and June 2007 at the 
Homerton University Hospital (an associate teaching hospital in an urban 
setting in London). During this period, approximately 6,000 deliveries took 
place. The population in the catchment area of this hospital has a high Afro- 
Caribbean ethnic mix and a high incidence of pre-eclampsia. 
Women and staffs awareness of the studies was raised by means of 
posters and fliers in antenatal clinic, the maternal-fetal assessment unit 
(MFAU), antenatal wards and labour ward. In the antenatal clinic, women 
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were assessed for eligibility for the 'normal values of PWA' study, and all 
eligible women were approached. Women diagnosed with pre-eclampsia or 
gestational hypertension, usually in the antenatal clinic, MFAU, antenatal and 
labour wards, were similarly assessed and eligible women approached. All 
women were given verbal and written information about the study for which 
they were eligible. Written informed consent was obtained from those who 
agreed to participate. 
2.2.2 Studies of the effect of antihypertensive therapy 
Women with a singleton pregnancy were prospectively recruited in the second 
and third trimesters. Exclusion criteria included multiple pregnancy, a history 
of hypertension, diabetes, renal disease or immune disorders, or women 
taking medication which could affect blood pressure. 
The study group in whom uterine artery Doppler, pulse wave analysis 
and maternal serum marker levels were measured are described in detail 
(including a COHORT flow diagram) in Section 3.1. They included 51 women 
presenting with pre-eclampsia, 29 with gestational hypertension and 80 
controls. All of these women had measurement of uterine artery Doppler, 
pulse wave analysis and serum levels of sFlt-1, sEng, PIGF, VEGF, inhibin A 
and activin A at the time of recruitment. The hypertensive group (n=80) had 
these measurements repeated 24-48 hours after starting anti hypertensive 
therapy. Another group of 48 women were recruited for measurement of 
placental levels: 24 with hypertensive disorders in pregnancy (14 pre- 
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eclampsia, 10 gestational hypertension), and 24 controls matched for 
maternal age, gestational age and parity. 
Blood pressure was measured in duplicate using a standard mercury 
sphygmomanometer and the average of two readings taken. All readings 
were taken by the same investigator (AK) with the subject in the sitting 
position. Korotkoff sounds 1 and 5 were used to define systolic and diastolic 
BP respectively. Mean BP was calculated as diastolic BP + 1/3 pulse pressure. 
Pre-eclampsia (PE) was defined according to the guidelines of the 
International Society for the Study of Hypertension in Pregnancy. ' Diagnosis 
required two recordings of diastolic blood pressure z 90 mm Hg, at least four 
hours apart; or one recording of diastolic BP 2: 120 mm Hg, in a previously 
normotensive woman; and urine protein excretion z 300 mg in 24 hours, or 
two readings of ++ or more on dipstick analysis of a midstream or catheter 
specimen of urine, if no 24 hour collection was available. 
Severe pre-eclampsia was defined as severe hypertension (diastolic 
blood pressure 21 10 mmHg) and mild proteinuria, or mild hypertension and 
severe proteinuria (a 24-hour urine sample that contained z3.5 g protein or a 
urine specimen z3+ protein by dipstick measurement). Patients with abnormal 
liver function (aspartate aminotransferase >70 IU/L) and thrombocytopenia 
(platelet count <100,000/cm3) were also classified as having severe pre- 
eclampsia. 
Gestational hypertension (GH) was defined as a diastolic blood 
pressure Z 90 mm Hg on at least two consecutive occasions in the second 
half of pregnancy, without proteinuria, in a previously normotensive woman. 322 
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Fetal growth restriction (FGR) was defined as birth weight less than the 
5th centile for gestational age. 
The controls consisted of 80 normotensive women matched for 
maternal age (± 3 years) and parity (none or one to two deliveries). All women 
in the control group had uncomplicated pregnancies. They had no history of 
cardiovascular disease, hypertension, proteinuria or fetal growth restriction, 
and were not taking medication that could affect blood pressure. 
We collected blood samples at similar gestational ages (± 4 days) from 
the hypertensive patients and matched controls. The diastolic blood pressure 
of all women with pre-eclampsia or gestational hypertension was higher than 
95 mm Hg. They received oral antihypertensive therapy in the form of alpha 
methyldopa 750-1500 mg/day for clinical indications according to local clinical 
guidelines. In accordance with local protocols, co-existing fetal growth 
restriction did not influence the decision to institute antihypertensive therapy. 
Venous blood was collected before and after (24-48 hours) antihypertensive 
therapy was commenced. A single venous blood sample was collected from 
controls. 
Placental samples were collected from another group of women (n = 
48) undergoing Caesarean section before the onset of labour, including 14 
presenting with pre-eclampsia, 10 with gestational hypertension and 24 
normotensive controls matched for gestational age (± 4 days), maternal age 
(± 3 years) and parity (none or one to two deliveries), and who were delivered 
by Caesarean section for obstetric reasons other than hypertension (e. g. 
preterm labour with an abnormal presentation or breech presentation at term). 
The hypertensive group included 12 women who received antenatal 
84 
antihypertensive therapy (alpha methyldopa 750-1500 mg/day). They were 
matched for gestational age with 12 women who were not taking 
anti hypertensive treatment. Four to five placental biopsies were obtained at 
random from the maternal surface of the placenta, free of placental 
membranes. 
2.2.3 Normal values of pulse wave analysis in pregnancy 
For this prospective study, a different group of women with singleton 
pregnancies (n = 665) attending for routine antenatal care and non-pregnant 
women (n = 44) who were members of staff were incidentally recruited to 
participate in the study. None of these women (pregnant or non-pregnant) had' 
a prior history of cardiovascular disease, chronic hypertension, diabetes, renal 
disease or immune disorders, and at the time of recruitment none was using 
medication which could affect blood pressure. All measurements in the non- 
pregnant women were taken during the follicular phase of their cycle. None 
was using hormonal contraception. 
Each of these women was followed up through pregnancy and had one 
or more (depending on gestation at recruitment) assessments with arterial 
pulse wave analysis. Women who developed pre-eclampsia, gestational 
hypertension, fetal growth restriction, spontaneous preterm labour, gestational 
diabetes, fetal abnormalities, or who had a miscarriage or termination of 
pregnancy, were excluded from analysis in this part of the study. 
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2.3 DATA COLLECTION 
Demographic and clinical data including age, body mass index (BMI), 
ethnicity, parity, blood pressure and gestational age (GA) were recorded for 
all recruited women. Gestational age was established on the basis of 
menstrual date and/or ultrasonographic examination prior to 20 weeks of 
gestation. All women were followed up until after delivery, and fetal and 
maternal outcomes were obtained from the women's medical records and 
labour ward records. 
2.4 UTERINE ARTERY DOPPLER ULTRASOUND 
Uterine artery Doppler indices were measured in the hypertensive and control 
groups at the time of recruitment. In women who received antihypertensive 
therapy, Doppler measurements were taken before and after (24-48 hours) 
therapy was initiated. The uterine artery was identified by a combination of 
real-time and colour Doppler techniques (iU22 Ultrasound System, Philips 
Medical Systems, Bothell, WA, USA). Blood velocity waveforms were 
recorded by the pulsed Doppler method (3.5 MHz curved probe; 120 Hz high- 
pass filter). 
The transducer was placed over the iliac fossa and the course of the 
uterine artery followed from the lateral pelvic wall across the external iliac 
artery (Figure 1.9a). Pulsed Doppler was then applied 1 cm medial to the 
crossover point. The angle of insonation used was less than 30 degrees. Five 
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consecutive flow velocity waveforms of good quality were recorded, and the 
pulsatility index and resistance index derived. 
The presence or absence of a diastolic notch in each uterine artery 
was noted (Figure 1.9c). A notch was considered to be present when there 
was a clearly defined upturn in the flow velocity waveform at the beginning of 
diastole, which was present in all recorded waveforms. 294 
2.5 ARTERIAL PULSE WAVE ANALYSIS 
All pulse wave analysis (PWA) measurements were performed in the same 
room at the same temperature (23 °C), after a period of rest of at least 10 
minutes. The women were asked to refrain from caffeine intake on the day of 
the study. During measurements, participants did not move or speak. Brachial 
artery blood pressure was measured in the non-dominant upper arm using a 
calibrated standard mercury sphygmomanometer. Brachial artery systolic BP 
was defined by the first Korotkoff sound and brachial diastolic BP by the fifth 
Korotkoff sound. 323 For each woman, the mean of two readings was used. 
Pulse pressure (PP) was defined as systolic minus diastolic pressure. The 
radial artery waveform was recorded using applanation tonometry, and the 
Sphygmocor® system (Atcor Medical, West Ryde, Australia) was used to 
analyse the radial artery wave contour. 277,324 The tip of the tonometer (a high 
fidelity pressure sensor) was pressed gently against the radial artery at the 
site of maximum pulsation at the wrist. This micromanometer precisely 
records pressure within the artery (Millar instruments, Houston, Texas. 
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USA). 252,253 A generalised transfer function 246,262,325 was applied to the radial 
artery waveform in order to derive the aortic waveform. 
After an initial learning period (approximately 20 repeated 
measurements), satisfactory reproducibility was achieved (< 5% variability 
between duplicate measurements in the same woman). The Sphygmocor® 
software incorporates a quality control feature (operator index) which is 
displayed on the screen, and which ensures that all recorded waveforms from 
the same patient are similar. Recordings were considered acceptable for the 
study when the operator index was > 90%. Reasonable confidence is gained 
if the pressure waveforms are consistent; the Sphygmocoro software 
compares waveforms and accepts a series only if similarity is within 
prescribed limits. Because there is a linear relationship between Aix and heart 
rate, Aix was standardised to a heart rate of 75 beats per minute (Alx-75). 255 
2.6 COLLECTION OF BLOOD SAMPLES 
Venous blood was collected from consenting participants. Ten mis of blood 
were collected into a vacuum tube and allowed to clot at room temperature for 
30 minutes. Serum was separated by centrifugation at 3,000 rpm for 10 
minutes and frozen in aliquots at -80 °C for further assay (see below). 
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2.7 COLLECTION OF PLACENTAL SAMPLES 
Four to five random placental biopsies were obtained from the maternal 
surface of the placenta, free of placental membranes. Placental samples were 
collected only from women who underwent Caesarean delivery (both cases 
and controls) in order to avoid the potential effect of labour on placental 
expression of the markers to be studied. The samples (placental villi, 164-559 
mg wet weight) were collected immediately after delivery and rinsed in sterile 
phosphate buffered saline (PBS), then snap frozen. 
2.8 ASSAYS FOR TGF BETA PROTEINS IN SERUM AND 
PLACENTA 
2.8.1 Assays 
All markers (sFlt-1, sEng, PIGF, VEGF, inhibin A and activin A) were assayed 
using the same principle -a quantitative sandwich enzyme immunoassay 
technique (Figure 2.1). After appropriate sample preparation (see below) and 
validation of the technique for placental assay, placental samples were 
processed in the same way. A monoclonal antibody specific for the marker 
was pre-coated onto a microplate. Standards and samples were then pipetted 
into the wells on the plate and any antigen present became bound by the 
immobilised antibody. After washing away any unbound substances, an 
enzyme linked polyclonal antibody specific for the marker being assayed was 
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added to the wells. Following a wash to remove any unbound antibody- 
enzyme reagent of antigen bound in the initial step, the colour development 
was stopped and the intensity of the colour measured. The optical density 
(OD) of each well was determined within 30 minutes, using a microplate 
reader set to either 490 nm (for inhibin A and activin A) or 540 nm (for sFlt-1, 
sEng, PIGF, VEGF). 
pp, 
il ,_Y Y 
Well coated with Add antigen Add second enzyme Add substrate 






Figure 2.1. Schematic representation of a sandwich ELISA assay. 
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2.8.2 Serum samples 
Inhibin A and activin A were measured using an in-house enzyme immune 
assay (ELISA) using monoclonal antibodies as both capture and detection 
antibodies. These assays are two-site 'sandwich' assays that use an ultra- 
sensitive detection system with alkaline phosphatase as the label (Figure 2.2). 
Inhibin A ELISA 
Inhibin A was measured using an in-house two-site ELISA previously 
validated for use in human serum. 187,326 Performed over two days, this ELISA 
uses monoclonal antibodies against the ßA subunit of inhibin A (E4) 327 as the 
capture antibody and the Fab' fragment of a monoclonal antibody against the 
a-subunit (R1) 328 conjugated to alkaline phosphatase as the second detection 




















Figure 2.2. Schematic representation of the inhibin A ELISA. 
Sample standards were prepared in inhibin A assay diluent (Appendix 1) 
using human recombinant inhibin A (National Institute for Biological 
Standards, Potters Bar, Herts, UK) in the following concentrations: 
500 pg/ml: 250 pg/mI: 125 pg/mI: 62.5 pg/mI: 
31.3 pg/ml: 15.6 pg/ml: 7.8 pg/mI: 3.6 pg/ml 
The minimum detection limit of this assay for human recombinant inhibin 
A was 2pg/ml. Inter- and intra-assay variability were 4.8% and 5.2% 
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respectively. Samples were tested in duplicate and any duplicates that 
showed greater than 15% difference in results were repeated. 
DAY1 
Prior to the assay, serum samples were defrosted, brought to room 
temperature and mixed thoroughly. A quality control (QC) pool was prepared 
from the serum of five study samples and used for each of the assay plates. 
Quality controls were diluted 1: 2,1: 5 and 1: 10 with inhibin A assay diluent 
(Appendix 1) and the blank samples were inhibin A assay diluent. Initially, a 
test assay was performed with different dilutions of the samples to derive the 
standard curve. One hundred and twenty five microlitres (Nis) of standards, 
samples, blanks and controls were pipetted into labelled tubes and 125 pis 
inhibin A assay diluent was added to each sample tube. 125 pis fetal calf 
serum was added to the standards and blanks (to overcome the matrix effect), 
following which 50 pis of 10% hydrogen peroxide (H202) was added to each 
well. Samples were mixed well and incubated for 15 to 30 minutes. 100 pis 
blanks, samples, standards and controls were transferred into duplicate wells 
from an ELISA E4 coated plate. The plate was then covered, placed in a 
moist box and incubated overnight at 4 °C. 
DAY 2 
Any unbound sample was discarded. The plates were then washed ten times 
with ELISA wash buffer (Appendix 2) using a Wellwash 4 Mk II plate washer 
(Thermo Electron Corp, Bioscience Technologies, Basingstoke, UK) and bang 
dried on paper towelling. 50 pls of anti-a subunit antibody conjugated to 
alkaline phosphatase (R1-alk phos) was added to each well and the plate 
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incubated for two hours at room temperature in a moist box. Any unbound 
antibody was then discarded and the plate washed 15 times on a plate 
washer followed by two manual washes using manual wash buffer (Appendix 
3). 
50 pls substrate (ELISA Amplification System, Invitrogen Life Technologies) 
was added to each well. After one hour of incubation at room temperature, 50 
pis amplifier was added to each well in the same sequence and timing as the 
substrate. When the blanks started to develop colour (after approximately ten 
minutes) the reaction was stopped with 50 pis per well of Stop solution 
(Appendix 4) and the plate was shaken for a few minutes. The plate was then 
read at 490 nm on an MRX 2 Microplate Reader (Dynex Technologies, 
Chantilly, VA, USA). 
Activin A ELISA 
The activin A ELISA is also a two-site assay specific for total activin A 
(follistatin-bound and unbound). 183'188 This assay uses the E4 monoclonal 
antibody as both the capture and detection antibody. The E4 used for 
detection is biotinylated; extravidin conjugated to alkaline phosphatase is 
incorporated into the assay as E4 cannot make a Fab' alkaline phosphate 
conjugate (Figure 2.3). A sodium dodecyl sulphate (SDS)/heat treatment is 
added which denatures follistatin to allow the measurement of total activin A 
and not just the free form. The detection limit of this assay for human 
recombinant activin A (Genentech, San Francisco, CA, USA) is 50 pg/ml. 
Intra- and inter-assay variations were 8.6% and 9.7% respectively. Any 
















Figure 2.3. Schematic representation of the activin A ELISA. 
An affinity purified human follicular fluid stock standardised against 
human recombinant activin A was used as standard. Standards were made 
up to the following concentrations using PBS plus 10% Bovine Serum 
Albumin (BSA) solution (Appendix 5): 
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10,000 pg/mI: 5,000 pg/mI: 2,500 pg/mI: 1,250 pg/mI: 
626 pg/mi: 312 pg/mI: 156 pg/mi: 78 pg/mI 
DAY 1 
Samples were defrosted as described above and the same quality control 
samples used. The blank samples were PBS plus 10% BSA. 175 pls of 
standards, samples, blanks and controls were added to labelled Eppendorf 
tubes. Then 175 pls 15% SDS were added to each tube and the tubes mixed 
by inversion. The tubes were then boiled at 85-95 °C for ten minutes. 
Samples were left to cool for a few minutes, then 30 pls of 30% H202 was 
added, and the samples mixed and incubated at room temperature for 10-20 
minutes. Using an E4 dry coated plate, 25 pis inhibin A assay diluent was 
added to each well and then 100 pis blanks, samples, standards and quality 
controls aliquoted in duplicate to each well. The plate was shaken for ten 
minutes on a plate shaker to allow mixing, then 25 pis of biotinylated E4 was 
added to all wells. The plate was covered and incubated at 4 °C in a moist 
box overnight. 
DAY 2 
Unbound sample was discarded and the plates washed ten times with ELISA 
wash buffer on a plate washer, then dried. To each well, 50 pis of extravidin 
conjugated to alkaline phosphatase (1 in 10,000 dilution) was added using a 
multi-head pipette. The plate was then incubated for two hours in a moist box 
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on a plate shaker. After incubation, the plate was washed 15 times on a plate 
washer, dried and then washed manually twice using manual wash buffer. 
250 pls manual wash buffer was added to each well and the plate was 
incubated on the plate shaker for ten minutes. This process was repeated 
and the buffer discarded. 
50 {Gis per well of substrate (ELISA amplification system, Invitrogen 
Life Technologies) was added and the plate incubated for one hour at room 
temperature in a moist box. After an hour, 50 pls of amplifier was added to 
each well. Once colour started to develop in the blank wells, the reaction was 
stopped with 50 pls per well of Stop solution and the plate shaken for a few 
minutes to mix the reagents. The plate was then read at 490 nm. 
Serum soluble fms-like tyrosine kinase 1 (sFlt-1) ELISA 
We used the Human Soluble VEGF R1/Flt-1 Immunoassay commercial 
Quantikine kit Catalogue Number DVR100B (R &D Systems, Minneapolis, 
Minnesota, USA) for assay of sFlt-1. 
Sample and standard preparation 
Samples were diluted up to 20-fold. To obtain 20-fold dilution, 20 pI samples 
were added to 380 pI calibrator diluent RD 6-10 (a buffered protein base with 
Sodium Azide and other preservatives). 
The VEGFR-1 standard was prepared as follows: standard 
recombinant human VEGFR-1 in a buffer, lyophilised, was reconstituted with 
ml of distilled water. This produced a stock solution of 20 ng/ml. The 
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standard was mixed to ensure complete reconstitution and was allowed to sit 
for a minimum of 15 minutes with gentle agitation prior to further dilution. 900 
pl of calibrator diluent RD 6-10 was pipetted into the 2000 pg/ml tube, and 500 
NI into the remaining tubes. 
The stock solution was used to produce the following dilution series: 
2000 pg/mI: 1000 pg/mI: 500 pg/mI: 250 pg/mI: 
125 pg/mI: 62.5 pg/mI: 31.2 pg/mI 
Each tube was mixed thoroughly before the next transfer. The blank tube (0 
standard) contained only calibrator diluent RD 6-10. 
Assay procedure 
A plate plan was written prior to commencement of the assay, in order to 
record standards and samples assayed. All reagents and samples were 
brought to room temperature before use. All samples, controls and standards 
were assayed in duplicate. 
100 pl of the assay diluent RD 1-68 (buffered solution) was added to 
each well. 100 pi of standard, control or sample was then added to each well. 
The plate was covered with an adhesive strip and incubated for two hours at 
room temperature on a horizontal microplate shaker set at 500 rpm. 
The plate was then washed four times with a wash buffer (400 pl of 
buffered surfactant) using a plate washer. After the last wash, any remaining 
wash buffer was removed by aspirating, then inverting the plate and striking it 
against clean paper towels. 200 pl of VEGFR-1 conjugate (polyclonal antibody 
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against VEGFR-1 conjugated to horseradish peroxidase) was added to each 
well. The plate was then covered with a new adhesive strip and incubated for 
a further two hours at room temperature on a plate shaker. Following this, the 
plate was washed four times as before. 
200 pl of substrate solution [a mixture of stabilised hydrogen peroxide 
and chromogen (Tetramethylbenzadine)] was then added to each well. The 
plate was incubated for 30 minutes at room temperature on the bench-top, 
protected from light. 50 pl of Stop solution (2N sulphuric acid) was then added 
to each well. The optical density of each well was then measured using a 
microplate reader and the concentration of sFIt-1 determined from the OD at 
540 nm. 
Serum soluble endoglin ELISA 
We used the Human Endoglin/CD105 commercial Immunoassay DuoSet'M kit 
(Catalogue Number DY1097, R&D Systems, Minneapolis, Minnesota, USA) 
for assay of soluble endoglin. 
Sample and standard preparation 
Samples were prepared as described above for sFlt-1 assay. The endoglin 
standard used was recombinant human endoglin in a buffered protein base, 
lyophilised. The calibrator diluent used was RD5K. The stock solution was 
used to produce the following dilution series: 
10 ng/mI: 5 ng/mI: 2.5 ng/mi: 1.25 ng/mI: 
0.625 ng/mI: 0.313 ng/mI: 0.156 ng/mI 
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Assay procedure 
Assay technique was similar to that described for sFlt-1. The assay diluent 
used was RD1 S (buffered protein base). The assay antibody was endoglin 
conjugate (mouse monoclonal antibody against human endoglin, conjugated 
to horseradish peroxidase). The concentration of sEng was determined from 
the OD at 540 nm. 
Serum PIGF ELISA 
We used the Human PIGF Immunoassay commercial Quantikine kit 
(Catalogue Number DPGOO, R&D Systems, Minneapolis, Minnesota, USA) 
for assay of placental growth factor. 
Sample and standard preparation 
Samples were prepared as described above for sFlt-1 assay. The PIGF 
standard used was recombinant human PIGF in a buffered protein base, 
lyophilised. The calibrator diluent used was RD6-11 (buffered protein base). 
The stock solution was used to produce the following dilution series: 
500 pg/mI: 250 pg/mI: 125 pg/mI: 
62.5 pg/mI: 31.2 pg/mI: 15.6 pg/mI 
Assay procedure 
Assay technique was similar to that described for sFlt-1. The assay diluent 
used was RD1-22 (buffered protein base). The assay antibody was PIGF 
100 
conjugate (polyclonal antibody against PIGF conjugated with horseradish 
peroxidase). The concentration of PIGF was determined from the OD at 540 
nm as described before. 
2.8.3 Placental samples 
Preparation of placental samples 
Placental biopsies were weighed in a sterile bottle and manually homogenised 
in four volumes (w/v) of Tris buffered saline containing EDTA-free serine- 
/cysteine-protease inhibitor cocktail, diluted according to the manufacturer's 
instructions (Roche Biochemicals) using a homogeniser. The protein extract 
was collected after centrifugation (3,000 rpm for 10 minutes) and stored at -80 
°C until quantitative analyses were performed in batches. 
Concentrations of placental markers are expressed per milligram of 
placental protein. Total placental protein concentration was determined using 
a commercial Coomassie DryTM protein assay (Bradford, UK). Placental 
markers were assayed in the same way as serum samples, using a 
quantitative sandwich enzyme immunoassay technique. 
Coomassie Dry Protein Assay 
Principle of the assay 
The assay as supplied already has the reagent dried in plate wells and 
prepared so that it dissolves rapidly when protein sample is added. The 
intensity of the blue colour produced by the reaction is proportional to the 
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concentration of protein present in the sample. This intensity can be 
measured in a microplate reader at 595 nm, and the optical density converted 
into protein concentration. The reagent dried in the wells is a modification of 
the Bradford reagent for total protein detection and quantification. Coomassie 
G-250 dye binds to protein and changes colour from reddish brown to blue, 
corresponding to an absorbance shift from 465 nm to 595 nm. 
Technique 
The standard was prepared using bovine serum albumin diluted in Phosphate 
Buffered Saline with the following dilutions: 
1000 mcg/mi: 500 mcg/mI: 250 mcg/mI: 
62.5 mcg/mI: 31.3 mcg/mi: 15.6 mcg/mI 
Samples were then prepared by diluting in PBS (1 in 50). Before use, assay 
plates were equilibrated to room temperature. 100 µl per well of blank, 
standard and samples were assayed in triplicate. The plate was shaken 
vigorously for 60 seconds until the solid dye was completely dissolved. The 
plate was then read in a microplate reader at 595 nm. The standard curve 
was plotted and the protein content calculated. Consistent timing between 
sample addition, plate mixing and absorbance measurement was ensured. 
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Placental VEGF ELISA 
We used R&D commercial DuoSet1' kits (Catalogue number DY293B, R&D 
Systems, Minneapolis, Minnesota, USA) for assay of placental VEGF. This 
assay employs the quantitative sandwich enzyme immuno-assay technique. 
The VEGF level in the serum samples was below the detectable levels. 
Sample preparation 
Placental samples were homogenised and the supernatant was stored at -80 
°C. Serial dilutions of the homogenate were prepared (neat, 1: 2,1: 5,1: 10, 
1: 20,1: 50,1: 100,1: 200). 
Plate preparation 
The capture antibody used was mouse anti-human VEGF. This was 
reconstituted with 1 ml of PBS to 180 pg/ml. This was then diluted with 12 mis 
of PBS to give a1 pg /ml (66.67 pl) solution. The plate was coated with 100 pl 
per well of capture antibody, then incubated overnight for 12-18 hours at room 
temperature in a moist box. 
The following day, the antibody remaining on the plate was discarded. 
The plate was washed three times using a wash buffer solution [0.05% Tween 
20 (Sigma) in PBS] 250 pl per well. The plate was then inverted and blotted 
dry against clean paper towels. 250 pl/well of blocking solution (1 % BSA in 
PBS) was added to the plate which was left for a minimum of one hour at 
room temperature. After an hour, the plate was washed three times by 
repeated aspiration and washing. 
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Standard preparation 
Recombinant VEGF was reconstituted with 0.5 mis of reagent diluent (1 % 
BSA in PBS) to a concentration of 120 pg/ml. Prior to making the dilutions, the 
standard was allowed to sit for a minimum of 15 minutes with gentle agitation. 
The stock was subsequently diluted by a factor of 55 to give a top standard 
(10 pl stock standard + 540 pl reagent diluent). The standards were diluted to 
give the following concentrations: 
2000 pg/mI: 1000 pg/ml: 500 pg/mI: 250 pg/mI: 
125 pg/mI: 62.5 pg/mI: 31.3 pg/mI 
Samples and quality control preparation 
Samples and quality controls were diluted using reagent diluent as follows: 
Up to 200-fold for samples from women with pre-eclampsia. 
Up to 100-fold for samples from women with gestational hypertension and 
from controls. 
These dilutions were derived from a dilution curve as previously described. 
Assay procedure 
A plate plan was written before starting the assay. After washing (blocking) 
the plate, 100 pl per well of the diluted standards, samples and quality 
controls were added in triplicate. The plate was then covered and incubated 
for two hours at room temperature. Following incubation, the plate was 
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washed three times by repeating the same cycle of aspiration and washing as 
before. 100 pl per well of detection antibody diluted reagent was added to the 
plate. 
The stock of the detection antibody was prepared by reconstituting 
biotinylated goat anti-human VEGF with 1 ml of reagent diluent to a 
concentration of 9 pl/ml. After reconstitution, the aliquots were stored at -80 
°C. The working concentration was 50 ng/ml (66.67 pI diluted in 12 mis of 
reagent diluent). The plate was covered and incubated for two hours at room 
temperature. Following incubation, the plate was washed three times as 
before. A1 in 200 dilution preparation of streptavidin-HRP was prepared by 
adding 60 ui of streptavidin conjugated to horseradish peroxidase to 12 mis of 
reagent diluent. 100 pl/well of this streptavidin-HRP was added to the plate, 
which was then covered and incubated for 20 minutes at room temperature in 
the dark. 
After 20 minutes, the plate was washed three times as before. A 
substrate solution was prepared as a 1: 1 mixture of colour reagent A (H202) 
and colour reagent B (tetramethylbenzidine). 100 Ng/welt of substrate solution 
was added to the plate, which was then incubated for a further 20 minutes at 
room temperature in the dark. 
50 pg/well of stop solution (2N H2SO4) was then added. The optical 
density of each well was determined using a microplate reader set to 540 nm. 
Placenta soluble endoglin assay 
Placental soluble endoglin was assayed using R&D commercial DuoSet"" 
human Endoglin (CD105) kits (Catalogue number DY1097). 
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Sample, standard and quality control preparation 
Samples were prepared as described above for placental VEGF assay. The 
capture antibody used was mouse anti-human endoglin. The standard used 
was recombinant human endoglin in a buffered protein base, lyophilised. The 
assay diluent used was 1% BSA in PBS. The standards were diluted to give 
the following concentrations: 
8000 pg/mI: 4000 pg/mI: 2000 pg/mI: 1000 pg/mI: 
500 pg/mI: 250 pg/mI: 125 pg/mI: 62.5 pg/mI 
The samples were diluted using reagent diluent as follows: 
Up to 200-fold for samples from women with pre-eclampsia. 
Up to 100-fold for samples from women with gestational hypertension and 
from controls. 
These dilutions were derived from the dilution curve as previously described. 
Assay Procedure 
Assay technique was similar to that described above for placental VEGF. The 
assay diluent used was 1% BSA in PBS. The detection antibody was 
biotinylated goat anti-human endoglin. The concentration of sEng was 
determined from the OD at 540 nm as described before. 
106 
Placental PIGF assay 
Placental PIGF was assayed using R&D commercial Duo SetTM human PIGF 
kits (Catalogue number DY264). 
Sample, standard and quality control preparation 
Samples were prepared as described above for placental VEGF assay. The 
capture antibody used was mouse anti-human PIGF. The PIGF standard used 
was recombinant human PIGF in a buffered protein base, lyophilised. The 
assay diluent was 1% BSA in PBS. The standards were diluted to give the 
following concentrations: 
2000 pg/mI: 1000 pg/mI: 500 pg/mI: 250 pg/mI: 
125 pg/mI: 62.5 pg/mI: 31.3 pg/mI 
The samples and quality controls were diluted in reagent diluent up to two-fold 
for all samples (from women with pre-eclampsia, women with gestational 
hypertension and controls). The dilution was derived from the dilution curve as 
previously described. 
Assay Procedure 
Assay technique was similar to that described for placental VEGF. The assay 
diluent used was 1% BSA in PBS. The detection antibody was biotinylated 
goat anti-human PIGF. The concentration of PIGF was determined from the 
OD at 540 nm. 
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Placental sFlt-1 assay 
We used the Human Soluble VEGF R1/Flt-1 commercial Immunoassay 
Quantikine kit (Catalogue number DVR100B, R&D Systems, Minneapolis, 
Minnesota, USA) for assay of sFIt-1. Sample and standard preparation, and 
assay procedure were identical to that used for serum sFlt-1 assay. 
Sample, standard and quality control preparation 
The samples were diluted using reagent diluent as follows: 
Up to 200-fold for samples from women with pre-eclampsia. 
Up to 100-fold for samples from women with gestational hypertension and 
from controls. 
These dilutions were derived from the dilution curve as previously described. 
Placental inhibin A assay 
Placental inhibin A was measured using the assay described above for serum 
assay, which was previously validated for placental extracts. 
329 187 326 
Sample, standard and quality control preparation 
This was as described for serum inhibin A assay, but inhibin A assay diluent 
(Appendix 1) was used instead of FCS. 
Placental samples were diluted using reagent diluent as follows: 
1 in 10 for samples from women with pre-eclampsia. 
1 in 5 for samples from women with gestational hypertension 
1 in 2 for samples from controls. 
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Placental activin A assay 
Placental activin A was measured using the assay described above for serum 
assay, which was previously validated for placental extracts. 
'83 330 329 
Sample, standard and quality control preparation 
This was as described for serum activin A assay, but the sample preparation 
step was different, using PBS+5% BSA sample buffer and 10% SIDS. 
Placental samples were diluted using reagent diluent as follows: 
1 in 20 for samples from women with pre-eclampsia. 
1 in 10 for samples from women with gestational hypertension 
I in 5 for samples from controls. 
Dilution curve 
Different pools of samples were prepared according to the condition (pre- 
eclampsia, gestational hypertension and controls) and gestational age (< 34 
weeks or z 34 weeks of gestation). Test assays were performed on these 
pools with various chosen dilutions. Appropriate dilutions were chosen for the 
different groups of samples. 
Validation 
The samples were diluted parallel to the standard curve (Figure 2.4). 
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Figure 2.4. Dilution curves for pre-eclampsia placental samples for (a) sFlt-1, 
(b) soluble endoglin, (c) PIGF and (d) VEGF. Standard curves were obtained 
using the respective standards in the ELISA. 
PE = pre-eclampsia 
2.9 DATA AND STATISTICAL ANALYSIS 
2.9.1 Power calculation 
For the 'normal values of PWA' study, a power calculation was performed in 
advance, although recognising that this calculation was based on the limited 
existing data about normal values in pregnancy. It was calculated that 144 
measurements in each trimester (including only one measurement per 
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woman) would provide the power to be 95% certain that the mean AIx75 
within each trimester was estimated within 2 of the correct value. 
There were even fewer data on which to base the power calculation for 
the studies examining the effects of antihypertensive therapy. There are no 
published studies reporting the effects of such therapy on levels of angiogenic 
and anti-angiogenic factors, inhibin or activin, either in pregnancy or in non- 
pregnant subjects. The data on the effect of anti hypertensive therapy on 
uterine artery Doppler resistance are conflicting. The power calculation for 
these studies was therefore based on studies of the effect of antihypertensive 
therapy on arterial stiffness as measured by PWA in non-pregnant 
hypertensive subjects. It was calculated that 27 women were needed in each 
hypertensive group to have 90% power to detect a difference of 2.5 
percentage points in augmentation index-75 at the 5% level. 
2.9.2 Effect of antihypertensive therapy on levels of markers and 
uterine artery Doppler in pregnancies with hypertensive disorders 
D'Agostino and Pearson Omnibus test was used to assess normality of 
continuous data. Analysis of variance (ANOVA) with Bonferroni post hoc tests 
were carried out to study the differences among the three groups: Data were 
analysed in two gestational age intervals: < 34 weeks (representing early 
onset disease) and z 34 weeks (representing late onset disease). Unpaired t 
test was used to compare the markers levels between mild and severe, and 
between early onset and late onset pre-eclampsia. Paired t test was used to 
compare marker levels before and after antihypertensive therapy. Unpaired t 
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test was used to compare placental marker levels in those who received 
antihypertensive therapy and those who did not. The data were normally 
distributed after logarithmic transformation. Pearson correlation analysis was 
carried out to investigate the relationship between the parameters measured. 
Data were analysed using SPSS® (SPSS version 15,2007, SPSS Inc., 
Chicago, Illinois, USA). GraphPad Prisms 5.0 for Windows (InStata, 
GraphPad Software Inc., San Diego, California, USA) was used to test the 
normality of data. Results were considered statistically significant at P<0.05. 
2.9.3 Effect of antihypertensive therapy on Pulse Wave Analysis in 
pregnancies with hypertensive disorders 
Baseline characteristics were compared using Chi-square test (Fisher's exact 
test when appropriate) for categorical variables and independent f-test for 
continuous variables. Although cases were matched to controls for maternal 
age, gestational age and parity, when comparing any two of the three groups 
(pre-eclampsia, gestational hypertension and controls), we chose to use 
unpaired t-test because of concerns that other differences between the 
groups in BMI, smoking status and ethnicity (which were not matched) could 
potentially bias the results. For comparison of all three groups, ANOVA with 
Dunnett's post-hoc test was used. Unpaired t test was used to compare the 
measurements between mild and severe, and between early onset and late 
onset pre-eclampsia. Measurements before and after starting 
antihypertensive therapy were compared using paired t-test. Data were 
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analysed using SPSS® (SPSS version 14.0,2005, SPSS Inc., Chicago, IL, 
USA). Multiple linear regression models were used to analyse the 
associations of AIx-75 with baseline characteristics and with haemodynamic 
parameters. 
2.9.4 Pulse Wave Analysis in normal human pregnancy and the effect 
of ethnicity 
Baseline characteristics were compared between pregnant and non-pregnant, 
and between the two ethnic groups, using Chi-square test (Fisher's exact test 
when appropriate) for categorical variables and independent t-test for 
continuous variables. Independent t-test was used to compare haemodynamic 
parameters between pregnant and non-pregnant, and between the two ethnic 
groups. For comparison of the three gestational age intervals, we used 
ANOVA multiple comparisons with Bonferroni post hoc testing. Multiple linear 
regression models were used to analyse the association of Pulse Wave 
Analysis parameters (AP and Alx-75) with baseline characteristics and with 
other haemodynamic parameters, such as blood pressure. A value of P<0.05 
was considered to be statistically significant. All P values were two-tailed. 
Data were analysed using SPSS® (SPSS version 14.0,2005, SPSS Inc., 
Chicago, IL, USA) and GraphPad Prism 5 (InStata, GraphPad, San Diego, 
CA, USA). 
Linear regression models were used for comparison of haemodynamic 
parameters between the study groups, adjusted for BP. When correcting for 
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BP between groups, mean pressure was the preferred parameter, as it is 
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Figures 3.1 (a) and (b) are flow diagrams describing the women recruited to 
the serum and placental arms of the study respectively. The baseline 
characteristics of the serum study groups are shown in Table 3.1. The time 
interval between the two measurements or sampling in the hypertensive 
women is also shown in Table 3.1. Among the 51 women with pre-eclampsia 
in this arm of the study, 16 (31%) had associated fetal growth restriction 
(FGR) and 8 (16%) had severe pre-eclampsia. All the severe pre-eclampsia 
cases were in the early-onset group. 
Of the 32 women recruited with gestational hypertension (16 < 34 
weeks and 16 z 34 weeks' gestation), 3 subsequently developed pre- 
eclampsia (3 in the gestational hypertension group recruited < 34 weeks and 
none in the gestational hypertension group recruited z 34 weeks' gestation) 
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Figure 3.1. Flow diagrams of women recruited to the serum (a) and placental 
(b) arms of the study respectively. 
Table 3.1. Baseline characteristics of the study groups in whom serum levels 
of markers, pulse wave analysis and uterine artery Doppler were measured, 
according to gestational age at recruitment. 
BMI = body mass index GA = gestational age 
Mean BP = mean blood pressure PE = pre-eclampsia 
GH = gestational hypertension 
t Data presented as mean ± SD and analysed by one-way ANOVA with 
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3.2 EFFECT OF ANTI HYPERTENSI VE THERAPY WITH 
ALPHA METHYLDOPA ON LEVELS OF ANGIOGENIC 
FACTORS IN PREGNANCIES WITH HYPERTENSIVE 
DISORDERS 
3.2.1 Results 
Serum levels prior to treatment 
Figure 3.2 shows the serum levels of angiogenic markers before and after 
antihypertensive therapy. Prior to treatment in women with pre-eclampsia, 
serum levels of sFlt-1 (Figure 3.2a) were significantly higher than 
normotensive controls (P <0.0001 both before 34 weeks and Z34 weeks), and 
higher than women with gestational hypertension (before 34 weeks, P <0.05; 
2: 34 weeks, P<0.0001). Serum sFlt-1 levels were also higher in gestational 
hypertension compared with controls (before 34 weeks, P <0.0001; z34 
weeks, P<0.05). Figure 3.2b shows that, prior to treatment in women with pre- 
eclampsia, serum PIGF levels were significantly lower than in controls (before 
34 weeks, P <0.0001; X34 weeks, P<0.01) but not significantly different from 
women with gestational hypertension. Levels in gestational hypertension were 
also significantly lower than in controls (before 34 weeks, P <0.0001; 234 
weeks, P<0.05). Figure 3.2c shows that, prior to treatment in women with pre- 
eclampsia, serum sEng was significantly higher than in normotensive controls 
(before 34 weeks, P <0.0001; 2: 34 weeks, P <0.01), and higher than women 
with gestational hypertension (before 34 weeks, P <0.0001; Z34 weeks, 
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P<0.05). Serum levels of sEng were not significantly different between 
gestational hypertension and normotensive controls. 
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Figure 3.2. Mean serum sFlt-1 (a), PIGF (b) and sEng (c) concentrations in 
normotensive women (controls), women with pre-eclampsia and women with 
gestational hypertension according to gestational age interval [early onset <34 
weeks (41 controls, 28 pre-eclampsia, 13 gestational hypertension) and late 
onset ? 34 weeks (39 controls, 23 pre-eclampsia, 16 gestational 
hypertension)]. Error bars represent standard errors. Comparison of controls 
and cases (with pre-eclampsia or gestational hypertension) was performed 
after logarithmic transformation. Levels before and after alpha methyldopa 
therapy are shown for women with pre-eclampsia and women with gestational 
hypertension. The levels in the three groups were compared using ANOVA 
with Bonferroni Dunn's posthoc tests. The levels before and after 
antihypertensive therapy are compared using the paired t test. ****P<0.0001, 
***P<0.001, **P<0.01, *P<0.05. P values are shown only for differences which 
are statistically significant. 
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ANOVA - P=0.01 ANOVA - P=0.004 
Figure 3.3 shows serum levels of these markers in early compared with 
late onset, and mild compared with severe pre-eclampsia. Serum levels of 
sFlt-1 were higher in early-onset compared with late-onset (P=0.002), and in 
severe compared with mild pre-eclampsia (P=0.004). Similarly, serum levels 
of sEng were higher in early-onset compared with late-onset (P=0.001), and in 
severe compared with mild pre-eclampsia (P<0.0001). Serum PIGF was lower 
in early-onset compared with late-onset (P=0.001), and in severe compared 
with mild pre-eclampsia (P<0.0001). 
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Figure 3.3. Mean maternal serum concentrations of sFlt-1 (a), PIGF (b) and 
soluble endoglin (c) in women with early onset and late onset pre-eclampsia 
(PE), and in women with mild and severe pre-eclampsia. Error bars represent 
standard errors. Early-onset were compared with late onset, and mild with 
severe pre-eclampsia after logarithmic transformation using unpaired t test. 
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Effect of treatment on serum levels 
Figure 3.2 shows the effect of treatment with methyldopa on serum levels of 
sFlt-1, PIGF and sEng. In women presenting with pre-eclampsia, 
antihypertensive treatment was associated with a significant fall in the serum 
concentrations of both sFlt-1 (before 34 weeks, P <0.01; Z34 weeks, P<0.001) 
and sEng (before 34 weeks, P <0.001; 2: 34 weeks, P<0.05) (Figures 3.2a and 
3.2c respectively). Anti hypertensive therapy had no significant effect on serum 
levels of PIGF in women with pre-eclampsia (Figure 3.2b) or on the level of 
any of these proteins in women with gestational hypertension. 
Placental levels in hypertensive disorders 
The results of the placental analysis are presented in Figure 3.4 and Table 
3.2. Figure 3.4 shows the placental extract concentrations of sFlt-1, PIGF, 
sEng, and VEGF in 24 controls, 14 pre-eclampsia cases and 10 gestational 
hypertension cases. Placental levels of sFlt-1 were significantly higher (5-fold) 
in pre-eclampsia compared with gestational hypertension (P<0.001) or 
controls (P<0.001). There was no significant difference in sFlt-1 levels 
between women with gestational hypertension and controls (Figure 3.4a). 
Placental levels of PIGF were significantly lower (P=0.01) in pre-eclampsia 
compared to controls (Figure 3.4b). Placental levels of PIGF were lower in 
gestational hypertension compared with controls but this difference did not 
achieve statistical significance (P=0.5). Placental concentrations of sEng were 
significantly higher (P<0.0001) in women with pre-eclampsia compared to 
gestational hypertension or normotensive controls (Figure 3.4c). There was 
no significant difference in placental sEng between controls and women with 
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gestational hypertension (P=0.07). Placental VEGF was significantly higher in 
women with either pre-eclampsia or gestational hypertension (P<0.0001) 
compared with normotensive controls (Figure 3.4d). There was no significant 
difference in placental VEGF between women with pre-eclampsia and women 
with gestational hypertension (P=0.6). 
Antihypertensive treatment and placental levels 
Table 3.2 shows the placental concentrations of the same four markers in 
women with pre-eclampsia and gestational hypertension, grouped according 
to whether they received anti hypertensive therapy (all with methyldopa) or 
not. In women with pre-eclampsia, treatment with methyldopa was associated 
with a significantly (almost 50%) lower placental concentration of sFIt-1 (P = 
0.01). In women with gestational hypertension, treatment was also associated 
with a lower placental sFlt-1 concentration but this did not achieve statistical 
significance (P=0.06). Anti hypertensive treatment was also associated with 
significantly (P =0.02) lower placental sEng in women with pre-eclampsia, but 
not in gestational hypertension. Treatment with methyldopa did not affect 
placental levels of PIGF or VEGF. 
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Figure 3.4. Concentrations of sFlt-1(a), PIGF (b), soluble endoglin (c) and 
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Figure 3.4. Concentrations of sFlt-1 (a), PIGF (b), soluble endoglin (c) and 
VEGF (d) in placental tissue (expressed per mg protein) from normotensive 
(controls), n= 24; pre-eclampsia (PE), n= 14; and gestational hypertension 
(GH), n= 10 pregnancies. Error bars represent standard errors. Comparison 
of controls and cases (with pre-eclampsia or gestational hypertension) was 
performed after logarithmic transformation. The mean gestational ages (days) 
for the three groups were (mean ± SD): controls 242 ± 16; pre-eclampsia 238 
± 13; gestational hypertension 243 ± 20. 
Table 3.2. Placental concentrations of sFlt-1, PIGF, sEng and VEGF 
(expressed per mg protein) in normotensive controls, pre-eclampsia and 
gestational hypertension, grouped according to whether they received 
antihypertensive therapy or not. The mean gestational ages for the three 
groups were (meant SD): controls 242 ± 16; pre-eclampsia 238 ± 13; 
gestational hypertension 243 ± 20. The P values represent the statistical 
difference between the groups with hypertension who received 
antihypertensive therapy or not. 
Data presented as mean (standard error of the mean) and analysed by 
independent t test. 
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The data from this study confirm that, in both early and late onset pre- 
eclampsia, maternal serum levels of sFlt-1 and sEng are higher, and PIGF 
lower, in women presenting with pre-eclampsia. 135,153,154 In addition, we found 
that placental sFIt-1 and sEng were significantly increased, and PIGF 
decreased, in women with pre-eclampsia compared to controls. Our data 
suggest that in pre-eclampsia placental concentrations of sFlt-1, sEng and 
PIGF mirror the maternal serum changes. These findings are consistent with 
the view that the placenta is the main source of sFlt-1, sEng and PIGF during 
pregnancy. 331 
Circulating sFlt-1 can bind to PIGF and VEGF, effectively inhibiting 
their actions. 128,131 Soluble FIt-1 is therefore considered to be a circulating 
anti-angiogenic factor. In our study, consistent with previous reports, 134,135 
levels of sFlt-1 were elevated and PIGF reduced in the serum of women with 
pre-eclampsia prior to treatment. The lower levels of free PIGF found in the 
serum of women with pre-eclampsia may be the result of impaired placental 
production or secretion, or due to increased binding by sFlt-1 in maternal 
serum. 
We found that placental concentration of VEGF was significantly higher 
in pre-eclampsia compared with controls. Although some studies have 
reported lower placental VEGF in pre-eclampsia '145,332 Trollmann et al 
333 
found increased VEGF mRNA expression in the placentas of women with pre- 
eclampsia (or women with acute fetal hypoxia) compared with gestational age 
matched controls. They also found increased in vitro expression of VEGF 
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mRNA in response to hypoxia. Immunohistological examination also 
demonstrated higher concentrations of VEGF protein in placental tissue, and 
particularly in placental vascular endothelial cells, of women with pre- 
eclampsia (or with acute fetal hypoxia) compared with controls. This points to 
a possible role for the VEGF system in the neovasculogenesis which occurs 
as an adaptive mechanism in response to placental hypoxia associated with 
pre-eclampsia. This is consistent with the finding that, in pre-eclampsia, 
placental VEGF protein expression increases in proportion to uterine artery 
resistance index. 334 
Our findings indicate that antihypertensive treatment with alpha 
methyldopa is associated with a significant fall in serum concentrations of 
both sFlt-1 and sEng in women presenting with either early onset or late onset 
pre-eclampsia. Methyldopa therapy had no significant effect on the serum 
levels of these markers in women presenting with gestational hypertension. 
Consistent with the trend in maternal serum, antihypertensive treatment with 
methyldopa was also associated with significantly lower placental 
concentrations of both sFlt-1 and sEng in pre-eclampsia, but not in gestational 
hypertension. These findings suggest that in pre-eclampsia alpha methyldopa 
may have a direct effect on placental synthesis and/or secretory functions and 
that this effect may not be simply the result of a reduction in maternal blood 
pressure and /or a change in utero-placental blood flow. However, sFlt-1 and 
sEng are also produced by vascular endothelial cells and we cannot exclude 
an endothelial cell effect of the medication in women with pre-eclampsia. The 
specific effect in pre-eclampsia (with no effect in gestational hypertension) 
indicates that methyldopa has a different effect on placental and/or endothelial 
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production and/or secretion of angiogenic factors depending on the 
pathophysiology of the hypertensive disorder. These findings support the 
concept of a difference in pathophysiology between gestational hypertension 
and the pathological endothelial toxic effect of pre-eclampsia. 
It has been shown that serum and placental sFlt-1 levels are elevated 
in women with established pre-eclampsia, 124,126-128,135-140,335 and the rise in 
serum sFlt-1 can be detected around five weeks before the onset of clinical 
disease. 135 We have shown that treatment of pre-eclampsia with methyldopa 
is associated with a reduction in serum and placental concentrations of sFlt-1. 
Yet it has previously been established that methyldopa therapy does not 
prevent pre-eclampsia. 336 These findings combined do not support the 
hypothesis that sFlt-1 plays a direct role in the pathophysiology of pre- 
eclampsia. 
Alpha methyldopa acts on a2-adrenergic receptors, primarily in the 
central nervous system although an effect on peripheral a2-adrenoreceptors 
may also play a part. 316,317 Its main active metabolite is alpha-methyl 
noradrenaline, which resembles noradrenaline in its effects. Stimulation of 
pre-synaptic a2-adrenoreceptors in the central nervous system leads to a 
reduction of central sympathetic outflow. This causes a reduction in blood 
pressure. 337 a2-adrenoreceptors have also been identified in a variety of other 
human tissues outside the central nervous system, including myometrium and 
placenta. 318,338 An almost universal effect of a2-adrenoreceptor stimulation is 




cAMP has been shown to be a strong inducer of Flt-1 expression 
in mice. 
341,342 
In 2007, it was demonstrated that down-regulation of a2R- 
adrenoceptors in mice placenta resulted in increased levels of Flt-1 and 
sFlt-1,343 suggesting that stimulation of a2ß-adrenoceptors can suppress 
production of sFlt-1. Deletion of the gene encoding a25-adrenoceptors resulted 
in upregulation of Flt-1 in spongiotrophoblast cells. These data support a 
direct link between adrenergic receptor signalling and angiogenic regulation 
by the VEGF system. This may be the mechanism by which alpha methyldopa 
leads to the reduction in sFlt-1 which our data support. Although this study 343 
was done in mice, several functionally relevant polymorphisms that may 
potentially affect sFlt-1 expression and blood vessel formation have been 
identified in human adrenoceptor genes. This adds weight to the argument 
that methyldopa has an effect on maternal production of vasoactive 
substances: the fact that we see a different response in women with pre- 
eclampsia may reflect the finding that women with this disease are producing 
abnormal amounts of these substances in the first place. 
Clinically, the need for antihypertensive treatment is a marker of 
disease severity; thus, prior to treatment, higher levels of sFlt-1 and sEng 
would be expected in the treatment group compared with the non-treatment 
group. Nevertheless, we found that antihypertensive treatment was 
associated with significantly lower levels of these two markers in the 
placentas of women treated with methyldopa compared to the placenta of 
untreated women. 
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It is not yet clear whether sFlt-1 and sEng are directly involved in the 
pathophysiology of pre-eclampsia or are simply markers of the disease 
process. Our data showing that antihypertensive treatment with alpha 
methyldopa is associated with a significant fall in their concentrations in both 
maternal serum and placenta is consistent with a positive effect on the control 
of disease progress. This finding supports the concept that pre-eclampsia 
combines an excessive maternal response to the presence of a pregnancy 
and placenta and progressive utero-placental insufficiency during the second 
half of pregnancy at the time of maximal fetal growth. 
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3.3 EFFECT OF ANTIHYPERTENSIVE THERAPY WITH 
ALPHA METHYLDOPA ON LEVELS OF INHIBIN A AND 




In pre-eclampsia, serum inhibin A (before 34 weeks, P<0.001; z 34 weeks, 
P=0.001) and activin A levels (before 34 weeks, P<O. 001;; -> 34 weeks, P<0. 
001) were significantly increased in both gestational age subgroups compared 
with controls (Figure 3.5). In gestational hypertension, serum inhibin A was 
significantly (P=0.002) higher than controls before 34 weeks but not z 34 
weeks, whereas activin A levels were significantly (P<0.0001) higher than 
controls in both subgroups. Serum levels of both inhibin A and activin A were 
significantly (P<0.001) higher in pre-eclampsia compared with gestational 
hypertension before 34 weeks but not z 34 weeks. In both pre-eclampsia 
gestational age subgroups, treatment with a-methyldopa was associated with 
a significant decrease in the serum levels of both inhibin A (before 34 weeks, 
P=0.04; z 34 weeks, P<0.001) and activin A (before 34 weeks, P=0.01; Z 34 
weeks, P=0.007). In contrast, in gestational hypertension treatment did not 
have a significant effect on their serum levels in either gestational age 
subgroup (inhibin A: before 34 weeks, P=0.2; z 34 weeks, P=0.5; and activin 
A: before 34 weeks, P=0.06; z 34 weeks, P=0.3). 
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Figure 3.5. Mean serum inhibin A (a) and activin A (b) concentrations in 
normotensives (controls), women with pre-eclampsia and women with 
gestational hypertension according to gestational age interval [< 34 weeks (41 
controls, 28 pre-eclampsia, 13 gestational hypertension) and >_ 34 weeks (39 
controls, 23 pre-eclampsia, 16 gestational hypertension)]. Error bars 
represent standard errors. Comparison of controls and cases (with pre- 
eclampsia or gestational hypertension) was performed after logarithmic 
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ANOVA - P=0.009 ANOVA - P<0.0001 
ANOVA - P<O. 0001 ANOVA - P<0.0001 
transformation. Levels before and after a-methyldopa therapy are shown for. 
women with pre-eclampsia and women with gestational hypertension. The 
levels in the three groups were compared using ANOVA with Bonferroni 
Dunn's posthoc tests. The levels before and after a-methyldopa therapy are 
compared using the paired t test. *"""P<0.0001, ***P<0.001, **P<0.01, 
*P<0.05. P values are shown only for differences which are statistically 
significant. 
Placental levels 
In both pre-eclampsia and gestational hypertension, placental concentrations 
of both inhibin A and activin A were significantly (P<0.001) higher than in 
controls (Figure 3.6). Placental levels of both markers were significantly 
(P<0.05) higher in pre-eclampsia compared to gestational hypertension. 
Significantly lower placental levels of inhibin A (P =0.02) and activin A (P 
=0.04) were found in women presenting with pre-eclampsia treated with a- 
methyldopa, compared with untreated women with pre-eclampsia (Table 3.3). 
After treatment, the levels of both hormones remained significantly (P<0.05) 
higher in pre-eclampsia than in controls. In gestational hypertension, 
treatment was not associated with a significant difference in the level of either 
hormone. 
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Figure 3.6. Concentrations of inhibin A (a) and activin A (b) in placental tissue 
(expressed per mg protein) from normotensive (controls, n= 24), pre- 
eclampsia (PE, n= 14) and gestational hypertension (GH, n= 10) 
pregnancies. Error bars represent standard errors. Comparison of controls 
and cases (with pre-eclampsia or gestational hypertension) was performed 
after logarithmic transformation. The mean gestational ages (days) for the 
three groups were (mean ± SD): controls 242 ± 16; pre-eclampsia 238 ± 13; 
gestational hypertension 243 ± 20. 
Table 3.3. Placental concentrations of inhibin A and activin A (expressed per 
mg protein) in women with pre-eclampsia (n = 14), women with gestational 
hypertension (n = 10) and controls (n = 24). Women with pre-eclampsia or 
gestational hypertension are grouped according to whether they received 
anti hypertensive therapy or not. The mean gestational ages for the three 
groups were (mean ± SD): pre-eclampsia 238 ± 13; gestational hypertension 
243 ± 20; controls 242 ± 16. The P values represent the statistical difference 
between the groups who received antihypertensive therapy and those who did 
not. 
Data presented as mean (standard error of the mean) and analysed by 
independent t test. 
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Our data confirm that inhibin A and activin A synthesis and secretion are 
increased in women presenting with hypertensive disorders in pregnancy and 
indicate for the first time that in pre-eclampsia placental production and 
circulating serum levels of these proteins decrease within 48 hours of initiating 
anti hypertensive treatment with alpha methyldopa. 
Serum levels of inhibin A and activin A increase several fold in women 
with pre-eclampsia and the pattern of changes in these levels is directly linked 
with the severity of the disease. 208 Placental secretion of inhibin A has also 
been shown to be increased in pre-eclampsia. 329 In the current study, we 
found that placental concentrations of inhibin A and activin A were 
significantly higher in pre-eclampsia compared with gestational hypertension. 
In both gestational hypertension and pre-eclampsia, placental levels of these 
proteins were higher than in normotensive controls. In women presenting with 
pre-eclampsia or gestational hypertension, serum levels of inhibin A and 
activin A reflected those in placental samples, suggesting that placental 
production/secretion of these markers is increased in both conditions, but to a 
greater extent in pre-eclampsia. Compared to late onset pre-eclampsia, early 
onset pre-eclampsia was associated with higher levels of both markers, 
supporting the view that these are more likely to represent different degrees of 
severity of the disease rather than distinct pathological entities. 
Overall, our data on the effect of antihypertensive therapy show that 
alpha methyldopa reduces the serum levels of inhibin A and activin A in both 
gestational age subgroups of pre-eclampsia but has no significant effect on 
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their levels in gestational hypertension at any gestation. In pre-eclampsia, 
placental levels of both hormones were also lower in women after 
antihypertensive therapy, although they remained higher than in normotensive 
controls (Table 3.3). These data suggest that the increased placental 
production/release of these markers in pre-eclampsia is partially, but not 
completely, reversed by alpha methyldopa therapy within the study period of 
48 hours. However, this effect was not observed in women presenting with 
gestational hypertension. The significant fall in serum inhibin A and activin A 
levels in pre-eclampsia but not in gestational hypertension, despite a similar 
effect on blood pressure, supports the view that different placental pathologies 
may be involved. For obvious reasons, it was not possible to measure 
placental concentrations of these markers before and after antihypertensive 
medication was started, so instead we compared placental levels in women 
who had this therapy and those who did not (Table 3.3). 
As discussed earlier (section 3.2.2), alpha methyldopa stimulates pre- 
synaptic a2-adrenoreceptors in the central nervous system, reducing central 
sympathetic outflow, which leads to a fall in blood pressure. 316,317,337 
a2-adrenoreceptors have been identified in a variety of other human 
tissues outside the central nervous system, including myometrium and 
placenta. 318,338 Stimulation of a2-adrenoreceptors inhibits adenyl cyclase, 
leading to decreased production of cAMP. 339,340 cAMP has been shown to 
increase the production of inhibin A and activin A in cultured human ovarian 
granulosa-luteal cells. 344 It has also been shown in the same tissue that cAMP 
induces mRNA for both the a and ßA subunits of inhibin A and activin A. 345 In 
k 
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fact, a subunit mRNA is induced via this cAMP-dependent pathway in a 
remarkably similar way in a variety of tissues in different species, including 
human. 346,347 It is therefore possible that alpha methyldopa stimulates 
placental a2-adrenoreceptors, reducing the production of cAMP which in turn 
leads to reduced production of inhibin A and activin A. 
It is also possible that antihypertensive medication directly affects 
trophoblasts to reduce production and/or secretion of inhibin A and activin A. 
Inflammatory cells produce activin A, and peripheral mononuclear cell 
secretion of activin A is increased in culture in the presence of inflammatory 
cytokines. 348"351 It has been shown that the inflammatory cytokines which are 
increased in pre-eclampsia stimulate placental trophoblast secretion of inhibin 
A and activin A. 352 Recently it was shown that anti hypertensive treatment can 
alter cytokine release in vitro; 353"3M4 this may explain the effect of 
antihypertensive drugs on placental content of inhibin A and activin A via 
cytokines in an autocrine/paracrine manner. However, since alpha 
methyldopa treatment does not cause any significant changes in women 
presenting with gestational hypertension, the mechanism by which it leads to 
r 
a fall in circulating levels of inhibin A and activin A in pre-eclamptic women 
remains to be elucidated. 
Activin A has been implicated in the regulation of endothelial cell 
function and, in combination with TGF-ß, may inhibit capillary endothelial cell 
growth. 355 Reduction in activin A levels by alpha methyldopa may therefore 
result in improved capillary endothelial cell function and growth. There is also 
evidence that activin A (with TGF-ß) stimulates growth of vascular smooth 
144 
muscle cells 356,357 so it is possible that a reduction in activin A levels may 
contribute to a reduction in peripheral vascular resistance. 
It is uncertain if inhibin A and activin A play a role in the 
pathophysiology of pre-eclampsia or are simply markers of the disease 
process. Nevertheless, the fact that anti hypertensive treatment with alpha 
methyldopa is associated with a fall in their serum and placental 
concentrations is likely to reflect a beneficial effect on the disease evolution 
over and above its known antihypertensive action. It is not yet known whether 
these drugs act directly on trophoblast cells to reduce production and/or 
release of these markers, or whether this effect may be mediated through 
other placental molecules. 
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3.4 EFFECT OF ANTIHYPERTENSIVE THERAPY WITH 
ALPHA METHYLDOPA ON CENTRAL HAEMODYNAMICS IN 
PREGNANCIES WITH HYPERTENSIVE DISORDERS 
3.4.1 Results 
Prior to antihypertensive treatment 
The haemodynamic parameters for each study group prior to treatment are 
presented and compared in Table 3.4. Mean arterial pressure, brachial and 
central systolic, diastolic and pulse pressures were all significantly (P<0.05) 
higher in both pre-eclampsia and gestational hypertension compared to the 
control group. There were no significant differences in brachial systolic, 
diastolic, pulse pressure or mean arterial pressure between the two 
hypertensive groups. Within each group (controls, pre-eclampsia, gestational 
hypertension) prior to treatment, there were no significant differences in 
augmentation pressure (AP) or augmentation index (Aix-75) between 
primigravid and multigravid women. 
Table 3.4. Heart rate, brachial and central haemodynamic measurements 
prior to antihypertensive therapy in women with pre-eclampsia (n=51), women 
with gestational hypertension (n=29) and matched controls (n=80). The 
measurements in pre-eclampsia and gestational hypertension are compared 
using the Student t test (P value in the last column). 
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Data are expressed as means ± SD. 














pressure (mm Hg) 
Central diastolic 
pressure (mm Hg) 
Central pulse 
pressure (mm Hg) 
Controls Pre- Gestational P 
eclampsia Hypertension value 
80 51 29 
82.0 (9.4) 81.0 (8.6) 82.7 (9.0) 0.4 
108.1 (11.6) 156.1 151.9 (17.8) * 0.2 
(10.6) * 
67.3 (8.0) 101.6 (7) * 99.3 (7.7) * 0.2 
40.8 (8.7) 54.4 
(11.6) * 
80.6 (8.8) 116.3 
(9.4) 
94.4 (10.0) 143.6 
(11.5) * 
68.5 (8.2) 103.4 
(6.8) * 
25.9 (5.6) 40.2 
(11.3) 
52.7 (12.6)" 0.5 
118.6 (18.9) * 0.5 
138 (15.9) 0.07 
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Figure 3.7. Augmentation pressure (a) and augmentation index at heart rate 
75/min (Alx-75) (b) measurements in normotensives (controls), women with 
pre-eclampsia and women with gestational hypertension according to 
gestational age interval [early onset <34 weeks (41 controls, 28 pre- 
eclampsia, 13 gestational hypertension) and late onset >_ 34 weeks (39 
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34 weeks or more 
I -II I 
ANOVA-P<0.001 ANOVA-P<0.001 
controls, 23 pre-eclampsia, 16 gestational hypertension)]. Error bars 
represent standard error of the mean. Measurements before and after alpha 
methyldopa therapy are shown for women with pre-eclampsia and women 
with gestational hypertension. The measurements in the three groups were 
compared using ANOVA with Bonferroni Dunn's posthoc tests. The levels 
before and after anti hypertensive therapy are compared using the paired t 
test. ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05. P values are shown only 




















" Early-onset PE 
O Late-onset PE 
Severe PE 
" Mild PE 
" Early-onset PE 
0 Late-onset PE 
" Severe PE 
" Mild PE 
Figure 3.8. Augmentation pressure (a) and augmentation index at heart rate 
75/min (Alx-75) (b) measurements in women with early onset (n=28) and late 
onset pre-eclampsia (n=23), and in women with mild (n=43) and severe pre- 
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Severity of preeclampsia 
Severity of preeclampsia 
eclampsia (n=8). Error bars represent standard deviation. Early onset were 
compared with late onset, and mild with severe pre-eclampsia using unpaired 
t tests. 
Effects of antihypertensive treatment 
Haemodynamic parameters before and after antihypertensive treatment are 
compared in Table 3.5. Peripheral and central pressures were all significantly 
(P<0.05) lower after treatment with alpha methyldopa. Figure 3.7 shows AP 
and Aix-75 before and after anti hypertensive therapy, stratified according to 
early onset (<34 weeks) or late onset (z 34 weeks) hypertension. Prior to 
treatment, both AP and Alx-75 were significantly higher in pre-eclampsia 
compared with normotensive controls (P<0.0001 for both). Similarly, both AP 
and Alx-75 were significantly higher in gestational hypertension compared 
with normotensive controls (P<0.05 and P<0.001). However, AP and Aix-75 
were significantly higher in pre-eclampsia compared with gestational 
hypertension (P<0.0001 and P<0.001 respectively), suggesting that pre- 
eclampsia is associated with a greater reduction in vascular compliance than 
gestational hypertension. 
Both AP and Alx-75 were significantly higher in early-onset versus late- 
onset pre-eclampsia (P< 0.0001) and in severe versus mild pre-eclampsia (P< 
0.0001) (Figure 3.8). 
Treatment with methyldopa was associated with a significant fall in heart 
rate in both pre-eclampsia and gestational hypertension. In pre-eclampsia, in 
both gestational age intervals, both AP and AIx-75 were significantly 
(P<0.0001) lower after treatment (Figure 3.7). In gestational hypertension, 
however, there was no significant change after treatment in either AP (< 34 
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weeks, P=0.2; z 34 weeks, P=0.7) or Aix-75 (< 34 weeks, P=0.7; Z 34 weeks, 
P=0.07). When we compared PWA indices between women with pre- 
eclampsia after antihypertensive therapy and the normotensive controls, a 
significant difference persisted for both AP and Aix-75 (P <0.0001 for both). 
Table 3.5. Brachial and central haemodynamic measurements in women with 
pre-eclampsia (n=51) and women with gestational hypertension (n=29). 
Measurements before and after alpha methyldopa therapy are compared 
using the paired t test. 
PE = pre-eclampsia GH = gestational hypertension 
Data are expressed as means ± SD 
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Haemodynamic PE PE P GH GH P 
variable before after value before after value 
N 51 51 29 29 
Heart rate (bpm) 81.0 77.1 <0.001 82.7 79.2 <0.001 
(8.6) (7) (9) (8) 
Brachial systolic 156.1 129.4 <0.001 151.9 138.2 0.023 
pressure (mmHg) (10.6) (15.2) (17.8) (19.6) 
Brachial diastolic 101.6 84.8 <0.001 99.3 87.0 <0.001 
pressure (mmHg) (7.0) (7.1) (7.7) (8.1) 
Brachial pulse 54.4 44.6 0.001 52.7 51.2 0.72 
pressure (mmHg) (11.6) (10.6) (12.6) (15.2) 
Central systolic 143.6 116.9 <0.001 138.0 124.1 0.01 
pressure (mm Hg) (11.5) (13.7) (15.9) (18.6) 
Central diastolic 103.4 86.3 <0.001 101.0 88.8 <0.001 
pressure (mm Hg) (6.8) (7.4) (8.0) (8.3) 
Central pulse 40.2 30.6 <0.001 37.0 35.3 0.6 
pressure (mm Hg) (11.3) (8.7) (10.9) (13.4) 
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3.4.2 Discussion 
Using pulse wave analysis, we have confirmed that vascular compliance is 
decreased in women with hypertensive disorders of pregnancy, particularly in 
pre-eclampsia. In pre-eclampsia, but not in gestational hypertension, vascular 
compliance is improved by treatment with alpha methyldopa. 
Each heartbeat generates a pulse wave which travels away from the 
heart. This waveform is reflected from bifurcations within the arterial tree and 
from the junctions of the pre-resistance and resistance vessels (see 
1.3.2). 250,358,359 The reflected wave travels back towards the heart and meets 
the advancing wave, augmenting its height (Figure 1.4). Generally, the 
reflected wave reaches the aorta during diastole, boosting the height of the 
diastolic portion of the wave. When arterial wall stiffness is increased (as in 
hypertensive disorders of pregnancy) the arterial pulse wave travels faster, so 
the reflected wave reaches the advancing wave in systole, resulting in 
significant augmentation of the systolic peak. This can be measured as raised 
augmentation pressure and augmentation index (Figure 1.8). 
Previous studies have demonstrated that, in normal pregnancy, aortic 
compliance increases in response to increased levels of oestrogen, mediated 
by increased circulating nitric oxide levels: resistance remains low until 
delivery. 281 The poor vascular compliance seen in women with hypertension 
probably reflects failure of the mother to adapt as well to the vascular 
challenge posed by the presence of a pregnancy. In a small observational 
study of 16 women with hypertensive disorders in pregnancy, 280 no difference 
in arterial stiffness was found between those receiving antihypertensive 
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treatment or not. However, haemodynamic parameters were compared 
between women who received treatment and those who did not; there are no 
data comparing women before and after treatment. 
It is estimated that 15-25% of women who present with gestational 
hypertension progress to pre-eclampsia. 360 We found that arterial stiffness is 
increased in gestational hypertension compared with normotensive pregnant 
women, but increased significantly more in women with pre-eclampsia. The 
differences in vascular compliance may be partly explained by changes in 
maternal blood volume; in pre-eclampsia, plasma volume is contracted 
whereas in gestational hypertension it may be unchanged or increased. The 
fact that AP and Aix-75 are higher in early onset compared with late onset, 
and severe compared with mild pre-eclampsia is consistent with the view that 
early and severe pre-eclampsia are part of the spectrum of the disease, and 
not different pathophysiological entities. Consistent with this, in another study, 
we found that first trimester PWA predicts early onset pre-eclampsia with 
greater accuracy than late onset. 361 
In pre-eclampsia, the improvement in arterial stiffness brought about by 
alpha methyldopa is probably due in part to normalisation of blood pressure 
(blood pressure increases arterial stiffness). 362,363 Even after anti hypertensive 
therapy, however, arterial stiffness remained higher when compared to 
normotensive pregnant women. This finding suggests that other factors are 
involved, such as poor vessel wall compliance and endothelial dysfunction, 
which contribute to the increased arterial stiffness but which are not corrected 
by antihypertensive treatment with alpha methyldopa. 
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Maternal heart rate fell significantly after treatment with methyldopa in 
both pre-eclampsia and gestational hypertension. This is consistent with 
previous reports. 364 After treatment, Aix-75 (which is adjusted for heart rate) 
was significantly reduced in pre-eclampsia but not gestational hypertension. 
The changes in AP (which is not adjusted for heart rate) after methyldopa 
treatment mirrored those in Aix-75, i. e. a fall in pre-eclampsia but no 
significant change in gestational hypertension. These findings suggest that 
the methyldopa-induced fall in maternal heart rate do not explain the 
changes we observed in arterial stiffness. 
Alpha methyldopa stimulates pre-synaptic a2-adrenergic receptors, 
primarily in the central nervous system, 316,317 leading to a reduction'of central 
sympathetic outflow and a reduction in blood pressure and heart 
rate. 
318,337,338,364 Vasodilator drugs probably have little direct effect on large 
central elastic arteries, but their effects on peripheral muscular arteries 
include a reduction in the amplitude of wave reflection and markedly lower 
systolic and pulse pressures. 250,267,358,359,3615-367 Therefore, the reflected wave 
takes longer to return, reaching the advancing wave later in diastole. The net 
result is less augmentation of the central waveform, which means that 
augmentation pressure and augmentation index are reduced. 
We have already shown that anti hypertensive therapy with alpha 
methyldopa in women with pre-eclampsia but not in gestational hypertension 
is associated with significantly reduced placental and serum levels of the anti- 
angiogenic factors sFlt-1 and soluble endoglin (Section 3.2). 368 The beneficial 
effect of this drug on arterial stiffness may be due to a direct effect on the 
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arterial wall or may be mediated through reduced circulating anti-angiogenic 
factors. These findings support the concept of a difference in pathophysiology 
between gestational hypertension and the pathological endothelial toxic effect 
of pre-eclampsia. 
Another possible explanation for the differential effect of methyldopa on 
arterial stiffness in pre-eclampsia and gestational hypertension involves its 
effect on the sympathetic system. Pre-eclampsia is associated with increased 
sympathetic tone. 369,370 Alpha methyldopa acts on a2-adrenoreceptors in the 
CNS, leading to a reduction in central sympathetic outflow. Thus it might be 
expected to bring about a greater reduction in vascular sympathetic tone and 
arterial stiffness in pre-eclampsia compared with gestational hypertension. 
Pulse wave analysis has previously been used to assess vaso-active 
medications, particularly antihypertensive drugs, in the non-pregnant 
population. For example, a randomised controlled study comparing atenolol 
and ramipril found that both cause a similar reduction in peripheral blood 
pressure. 265 However, the fall in central systolic pressure is significantly 
greater with ramipril. Pulse wave analysis showed that this difference is due to 
the greater reduction in arterial stiffness caused by ramipril, and probably 
explains its greater long-term benefits. Studies such as these have led to a 
significant change in guidelines for managing hypertension in the non- 
pregnant population. 27 Our findings suggest that pulse wave analysis may 
also have an important role to play in the assessment of new and existing 
anti hypertensive medications used in pregnancy, so that central - as well as 
peripheral - effects can be determined. 274,275,359 
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Ideally, we would have included in our study a group of women with a 
similar degree of pre-eclampsia who did not receive anti hypertensive therapy 
and another group of normotensive women who did. However, because of 
ethical concerns about the potential effects of such management, this was not 
possible. 
Our findings suggest that any future research into pulse wave analysis 
in hypertensive disorders of pregnancy should be mindful of possible effects 
of anti hypertensive therapy. Further research is needed to evaluate the effect 
of prolonged anti hypertensive therapy, and whether different antihypertensive 
drugs have differential beneficial effects on maternal central haemodynamics. 
Such research will improve our understanding of the pathophysiology of pre- 
eclampsia but may also lead to better therapeutic clinical protocols. Women 
who develop pre-eclampsia are at significantly increased risk, later in life, of 
cardiovascular disease such as ischaemic heart disease and stroke. It is not 
known whether the beneficial effect of antihypertensive treatment in 
pregnancy on pulse wave analysis could modify this long-term risk. 
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3.5 EFFECT OF ANTIHYPERTENSIVE THERAPY WITH 
ALPHA METHYLDOPA ON UTERINE ARTERY DOPPLER IN 
PREGNANCIES WITH HYPERTENSIVE DISORDERS 
3.5.1 Results 
Prior to treatment 
Before 34 weeks' gestation, prior to treatment, mean (SD) uterine artery 
pulsatility index (PI) was significantly higher in women with pre-eclampsia 
than in women with gestational hypertension: 1.51 (0.45) versus 0.85 (0.19), 
P<0.0001; or controls: 1.51 (0.45) versus 0.84 (0.16), P<0.0001 (Figure 2a). 
However, before 34 weeks there was no significant difference between 
women with gestational hypertension and controls: 0.85 (0.19) versus 0.84 
(0.16), P=0.95. 
A similar pattern of results was seen Z 34 weeks' gestation prior to 
treatment (Figure 3.9). Mean (SD) PI in women with pre-eclampsia was 
significantly higher compared with women with gestational hypertension: 0.79 
(0.12) versus 0.61 (0.11), P<0.0001; or controls: 0.79 (0.12) versus 0.62 
(0.13), P<0.0001. Neither was there any significant difference between 
women with gestational hypertension prior to treatment and controls: 0.61 
(0.11) versus 0.62 (0.13), P=0.95. 
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Figure 3.9. Uterine artery Doppler mean Pulsatility Index before and after 
anti hypertensive therapy in women with pre-eclampsia or gestational 
hypertension, and in normotensive controls, stratified according to gestation. 
Mean resistance index measurements followed a similar pattern (Figure 3.10). 
Prior to treatment before 34 weeks' gestation in women with pre-eclampsia, 
mean (SD) RI was significantly higher than in women with gestational 
hypertension: 0.72 (0.07) versus 0.44 (0.05), P<0.0001; or in controls: 0.72 
(0.07) versus 0.45 (0.07), P<0.0001. Below 34 weeks' gestation, there was no 
significant difference between women with gestational hypertension prior to 
treatment and controls: 0.44 (0.05) versus 0.45 (0.07), P=0.6. 
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Figure 3.10. Uterine artery Doppler mean Resistance Index before and after 
antihypertensive therapy in women with pre-eclampsia or gestational 
hypertension, and in normotensive controls, stratified according to gestation. 
After 34 weeks, the mean (SD) RI was significantly higher in women with 
pre-eclampsia prior to treatment than in women with gestational hypertension: 
0.65 (0.03) versus 0.40 (0.02), P<0.0001; and in controls: 0.65 (0.003) versus 
0.42 (0.03), P<0.0001 (Figure 3.10). At this gestation, there was also no 
significant difference between women with gestational hypertension prior to 
treatment and controls: 0.40 (0.02) versus 0.42 (0.03), P=0.4. 
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Effect of antihypertensive therapy 
Figure 3.9 shows the uterine artery Doppler PI measurements in women with 
pre-eclampsia and gestational hypertension, before and after anti hypertensive 
treatment with methyldopa, stratified according to gestation (< 34 weeks or z 
34 weeks). In women with pre-eclampsia, there was no significant difference 
in the mean (SD) uterine artery PI before and after treatment, in either 
gestational age interval: < 34 weeks: 1.51 (0.45) versus 1.48 (0.47), P14.07; 
34 weeks: 0.79 (0.12) versus 0.79 (0.11), P=0.61. Similarly, in women with 
gestational hypertension, there was no significant difference before and after 
treatment: < 34 weeks: 0.85 (0.19) versus 0.84 (0.20), P=0.6; z 34 weeks: 
0.61 (0.11) versus 0.61 (0.12), P=0.4. 
Anti hypertensive treatment was not associated with any significant 
changes in mean RI in women with either pre-eclampsia or gestational 
hypertension, at any gestation (Figure 3.10). In women with pre-eclampsia 
prior to 34 weeks, the mean (SD) RI before and after treatment was: 0.72 
(0.07) versus 0.71 (0.07), P=0.06. The equivalent figures for women with 
gestational hypertension were: 0.43 (0.05) versus 0.44 (0.04), P=0.2. After 34 
weeks' gestation, mean (SD) RI in women with pre-eclampsia before and after 
treatment was: 0.65 (0.03) versus 0.66 (0.04), P=0.5. The equivalent figures 
for women with gestational hypertension after 34 weeks were: 0.40 (0.02) 
versus 0.40 (0.02), P=0.58. 
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Early onset versus late onset disease 
We further analysed women with pre-eclampsia, comparing those with early 
onset versus late onset, and those with severe versus mild pre-eclampsia. 
The mean (SD) uterine artery PI was significantly higher in early onset 
compared with late onset pre-eclampsia. 1.51(0.45) versus 0.79 (0.12), 
P<0.0001; and in women with severe compared with mild disease: 1.86 (0.45) 
versus 1.06 (0.39), P<0.0001 (Figure 3.11). 
A similar pattern was seen in resistance index measurements (Figure 
3.12). Mean (SD) RI was significantly higher in women with early onset versus 
late onset pre-eclampsia: 0.72 (0.07) versus 0.65 (0.03), P<0.0001; and in 
women with severe versus mild pre-eclampsia: 0.80 (0.05) versus 0.67 (0.04), 
P<0.0001. 
P<n nnm 
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Figure 3.11. Uterine artery Doppler mean Pulsatility Index in women with 
early compared with late onset, and severe compared with mild pre- 
eclampsia. 
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Figure 3.12. Uterine artery Doppler mean Resistance Index in women with 
early compared with late onset, and severe compared with mild pre- 
eclampsia. 
3.5.2 Discussion 
We found that, prior to treatment, uterine artery indices of resistance were 
higher in women with pre-eclampsia compared with women with gestational 
hypertension or controls, both before and after 34 weeks' gestation. There 
was no significant difference in resistance between women with gestational 
hypertension prior to treatment and controls. Treatment with anti hypertensive 
medication did not significantly affect these indices in either pre-eclampsia or 
gestational hypertension, either before or after 34 weeks' gestation. Early 
onset and severe pre-eclampsia were associated with higher resistance 
indices. 
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Our study confirms the findings of other studies that the indices of uterine 
artery resistance are increased in women with pre-eclampsia, 296,297,371-374 but 
not in women with gestational hypertension, which remained the same as in 
normotensive controls. This impairment in uteroplacental perfusion found in 
pre-eclampsia but not in gestational hypertension may in part explain the poor 
fetal and neonatal outcomes in the former. 375,376 One study 376 compared 
pregnancy outcomes in women with pre-eclampsia, non-proteinuric 
gestational hypertension and chronic hypertension. Compared with non- 
proteinuric hypertensive patients, women with pre-eclampsia delivered 
significantly earlier (35.3 versus 38.6 weeks) with a lower birth weight (1997 
versus 2922 gm) and higher rates of preterm delivery (58% versus 10%), 
small for gestational age infants (52% versus 18%) and perinatal death (13% 
versus 3%). 
Nevertheless, it must be highlighted that adverse perinatal outcomes 
also occur in gestational hypertension. 377 It has also been confirmed that 
maternal and fetal complications are more common in hypertensive women 
with proteinuria than in hypertensive women without proteinuria. 378 However, 
in this study, even the non-proteinuric hypertensive women had a higher rate 
of maternal complications compared with normotensive controls (4% versus 
13%), confirming that non-proteinuric hypertension is a pathological condition. 
One study published in 2003 379 showed that, as expected, abnormal 
uterine artery Doppler waveforms were common in women with pre-eclampsia 
(164/186) compared with women with gestational hypertension (71/158). 
However, in both groups (pre-eclampsia and gestational hypertension), the 
presence of abnormal uterine artery Dopplers was related to the risk of poor 
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pregnancy outcome. The authors of this study concluded that "patients with 
gestational hypertension without proteinuria but with abnormal uterine artery 
velocimetry have pregnancy outcomes that do not differ significantly from the 
outcomes of pre-eclamptic patients, in terms of week at delivery, birth weight, 
and frequency of growth restricted fetuses". 
We found that methyldopa therapy had no significant effect on uterine 
artery Doppler resistance in women with -pre-eclampsia or gestational 
hypertension. Four previous studies have examined the effect of methyldopa 
on uterine artery Doppler indices in women with hypertensive disorders of 
pregnancy. 372,380-38e These studies yielded mixed results. In a study 380 of 20 
women with pre-eclampsia in the third trimester receiving 750 mg of 
methyldopa daily for a week, no significant effect was found on uterine artery 
PI. Another study by the same authors 381 examining the effects of isradipine 
and methyldopa did not find an effect on uterine artery Pl. In contrast, a study 
by Rey et a1382 compared 25 women with pre-eclampsia (14 on treatment, 11 
untreated), 43 women with chronic hypertension (14 on treatment, 29 
untreated) and 22 normotensive controls. Women were treated with 
methyldopa 750 mg daily for a week. There was a significant decrease in 
placental artery PI in women taking methyldopa compared with those 
untreated, in both the pre-eclamptic and chronic hypertensive groups. The 
most recent of these studies 372 compared 24 women with pre-eclampsia 
treated with 1g of methyldopa per day for a week, with 20 normotensive 
pregnant controls. Uterine artery PI, RI and S/D were significantly lower after 
antihypertensive therapy. Ours is the single biggest study of the effect of 
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methyldopa on uterine artery indices in women with hypertensive disorders of 
pregnancy. We found no significant effect in either pre-eclampsia or 
gestational hypertension, either before or after 34 weeks' gestation. 
It is clinically relevant that our study shows no adverse effects of 
methyldopa treatment on uteroplacental perfusion because there is a 
theoretical concern that anti hypertensive treatment in women with pre- 
eclampsia might adversely affect uteroplacental perfusion by reducing blood 
pressure when there is already increased uterine artery resistance. 
383,384 
Furthermore, it has been suggested that antihypertensive treatment should be 
preceded by plasma expansion with intravenous fluids. 385 Our findings 
suggest that volume expansion prior to anti hypertensive treatment with 
methyldopa in these women is not necessary; this therapeutic approach might 
be useful for women treated with vasodilators. 
Conversely, treatment with methyldopa, the anti hypertensive most 
commonly used in women with pre-eclampsia in the United Kingdom, does 
not improve uteroplacental perfusion. This observation is consistent with the 
findings of a systematic review that antihypertensive drug therapy for mild to 
moderate hypertension during pregnancy has no beneficial effect on the risk 
of fetal demise (relative risk 0.73,95% Cl 0.50 to 1.08), small for gestational 
age babies (relative risk 1.04,95% CI 0.84 to 1.27) or on any other adverse 
fetal outcome. 336 Overall, the main benefit of anti hypertensive treatment in 
these women is an improvement in maternal outcome, in particular a halving 
of the risk of developing severe hypertension (relative risk 0.50,95% CI 0.41 
to 0.61). 
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3.6 PULSE WAVE ANALYSIS: NORMAL VALUES IN 
PREGNANCY 
3.6.1 Results 
Of the 665 pregnant women studied, 24 (3.6%) developed pre-eclampsia, 36 
(5.4%) non-proteinuric gestational hypertension and 17 (2.6%) fetal growth 
restriction. We also excluded 20 women (3.0%) with spontaneous preterm 
labour, 9 (1.3%) with gestational diabetes, 4 (0.6%) who had a miscarriage, 4 
(0.6%) who had fetal abnormalities and underwent termination of pregnancy, 
and 10 (1.5%) whose outcomes were missing. This left 541 healthy 
normotensive pregnant women and 44 non-pregnant women eligible for 
subsequent analysis. Of these 541 women, 154 were recruited in the first and 
early second trimester (8+1 to 13+6 weeks), 209 in the second trimester (14+0 
to 26+0 weeks), and 178 in the late second trimester and third trimester (26+1 
to 39+0 weeks). Of the 154 women recruited in the first trimester, 45 had 
measurements taken at 12+0-12+6 weeks, 23+0-23+6 weeks, and 32+0-32+6 
weeks of gestation; these longitudinal data were analysed separately. 
The baseline characteristics of the two normotensive study groups 
(pregnant and non-pregnant) are shown in Table 3.6. There were no 
statistically significant differences between the two groups. Similarly, there 
were no significant differences in baseline characteristics among women 
recruited in the three trimesters. 
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Table 3.6. Baseline characteristics of pregnant and non-pregnant women. 
BMI = body mass index 
Data are expressed as means ± SD or as percentages 
Pregnant Non-pregnant P value 
N=541 n=44 
Age (years) 30.5 (6) 31 (6) 0.6 
BMI (kg/m2) 27 (5) 27 (5) 1 
Nulliparity n (%) 242 (45) 17 (39) 0.4 
Caucasian n (%) 229 (42) 18 (41) 0.9 
Smokers n (%) 78 (14) 7 (14) 0.8 
Table 3.7 shows the haemodynamic parameters for the same two study 
groups. Heart rate was significantly faster (P <0.001), and AP and Alx-75 
significantly lower (P =0.004, P =0.01), in normotensive pregnant women 
compared with non-pregnant. 
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Table 3.7. Haemodynamic parameters in pregnant and non-pregnant women. 
Parameter Pregnant Non- P value 
pregnant 
n=541 n=44 
Brachial systolic BP (mmHg) 109 (16) 109 (17) 1 
Brachial diastolic BP 68 (9) 70 (9) 0.1 
(mmHg) 
Brachial pulse pressure 41 (12) 39(11) 0.2 
(mmHg) 
Mean BP (mmHg) 83(11) 84(12) 0.4 
Heart rate (bpm) 87 (15) 75 (12) < 0.001 
Central systolic BP (mmHg) 97 (14) 99 (16) 0.3 
Central diastolic BP (mmHg) 70 (9) 71 (9) 0.4 
Central pulse pressure 27 (9) 28 (9) 0.5 
(mmHg) 
AP (mmHg) 3.5(4) 5.5(4) 0.004 
Alx-75 (%) 16(11) 20.4 (12) 0.01 
BP = blood pressure 
bpm = beats per minute 
AP = augmentation pressure 
Aix-75 = augmentation index at heart rate 75 beats per minute 
Data are expressed as means ± SD or as percentages 
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We compared the haemodynamic parameters for the normotensive 
pregnant women according to trimester. There were no significant changes in 
AP or Aix-75 as pregnancy progressed. There was no significant change in 
either brachial systolic or diastolic BP from trimester to trimester, but brachial 
pulse pressure was significantly lower in the third trimester compared with the 
second. Heart rate rose significantly from first to second (P <0.001) and 
second to third trimester (P <0.001). The changes in central diastolic blood 
pressure approached significance (P =0.055) and the post hoc comparison 
showed a significant difference between the second and third trimesters (P 
=0.045), rising from a mean (SD) of 68.8 (8.7) to 71.1 (10.5). The changes in 
AP and Alx-75 according to days of gestation are shown in Figure 3.13 (AP: 
r=-0.01, P =0.80; Aix-75: r=0.04, P =0.34). The monthly changes in Alx-75, 
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Figure 3.13. Pulse wave analysis parameters according to gestation. Scatter 
plots of (a) augmentation pressure (AP), and (b) augmentation index at heart 
rate of 75/min (Alx-75) according to the gestational age in days (n = 541). The 
5th and 95th centiles are shown. 
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Figure 3.14. Monthly changes in augmentation index at heart rate 
75/min (Alx-75), central and peripheral blood pressure. Monthly [10+0.13+6 
weeks (n = 145), 14+0-17+6 weeks (n = 56 ), 18+0-21+6 weeks (n = 55 ), 22+0- 
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25+6 weeks (n = 104), 26+0-29+6 weeks (n = 86), 30+0-33+6 weeks (n = 57) and 
34+0-37+s weeks of gestation (n = 38)] changes throughout pregnancy in: (a) 
Aix-75 and (b) brachial and aortic blood pressures. Values represent mean 
values and error bars represent standard errors. 
BP = blood pressure 
Figure 3.15 shows the longitudinal data for the 45 normotensive 
women who had measurements taken at 12+0-12+6 weeks, 23+0-23+6 weeks, 
and 32+0-32+6 weeks of gestation. The fall in both AP and Alx-75 in the 
second trimester and the rise in both parameters in the third trimester were 
statistically significant (P<0.001). There was a non-significant drop in mean 
blood pressure in the second trimester and a rise again in the third trimester. 
We studied 229 Caucasian and 216 pregnant Afrocaribbean 
normotensive women. Baseline characteristics of these two major ethnic 
groups were compared; these included age, BMI, parity, smoking, gestational 
age at recruitment, brachial and central pressures (systolic, diastolic, pulse 
pressure and mean arterial pressure) and heart rate. The only significant 
difference was a greater body mass index in Afrocaribbean compared with 
Caucasian women (P=0.003). The numbers of Caucasian and Afrocaribbean 
women respectively recruited in each trimester were: 11+0 to 13+6 weeks, 68 
and 60; 14+0 to 26+° weeks, 87 and 88; 26+1 to 33+0 weeks, 74 and 68. There 
were no statistically significant differences in AP or Alx-75 between these two 
ethnic groups in any trimester. 
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Figure 3.15. Longitudinal changes in pulse wave analysis parameters. 
Longitudinal data for the 45 women who had measurements taken at 12+0- 
12+6 weeks, 23+0-23+6 weeks, and 32+0-32+6 weeks of gestation: (a) 
augmentation pressure and (b) augmentation index at heart rate 75 beats per 
minute (AIx-75). 
3.6.2 Discussion 
This study establishes the normal ranges for pulse wave analysis parameters 
in normal pregnancy. We found no significant differences in these parameters 
between the two main ethnic groups in our population. Arterial stiffness was 
significantly lower in pregnant compared with non-pregnant women, 
confirming the findings of previous studies. 2$1,282 This is also consistent with 
the known vasorelaxation of pregnancy caused by vasoactive agents such as 
progesterone and relaxin. 
386-389 
Augmentation index has a linear relationship with heart rate, 255 
highlighting the importance of controlling augmentation index for pulse rate 
and thus the need in pregnancy to use AIx-75 rather than AN. 
Our study confirms that, in normal pregnancy, aortic stiffness varies 
throughout pregnancy, reaching its nadir in the second trimester and rising 
again in the third. 282 Individual women followed longitudinally throughout 
pregnancy had a significant fall in arterial stiffness (Alx-75) in the second 
trimester, with a significant rise again in the third. These changes were not 
linked to variations in blood pressure, which in our population did not change 
significantly through pregnancy, or to changes in heart rate, which rose 
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consistently throughout pregnancy and was controlled for in Alx-75. These 
results suggest that changes in arterial stiffness may result from changes in 
the levels of vasoactive substances such as progesterone and relaxin, and 
volume expansion of pregnancy. When we pooled our data, we found no 
significant changes in mean AP and AIx-75 from one trimester to the next. 
However, we observed a trend towards a fall in Alx-75 in the second trimester 
and a rise in the third, consistent with the trend seen in the sub-group of 
women followed longitudinally. 
Arterial pulse wave analysis is non-invasive and easy to learn. The 
equipment is inexpensive and portable and can be easily used in the 
outpatient setting. This study establishes normal values for pulse wave 
analysis parameters in all three trimesters and in Caucasian and 
Afrocaribbean women. These data may be used as the basis for further 
investigation into the role of pulse wave analysis in the assessment, 
management and perhaps prediction of pre-eclampsia. 
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3.7 SUMMARY OF FINDINGS 
In pre-eclampsia, maternal serum and placental levels of sFlt-1 and sEng are 
higher, and PIGF lower, compared with controls. Anti hypertensive treatment 
with alpha methyldopa is associated with significantly lower serum and 
placental concentrations of both sFlt-1 and sEng in women presenting with 
pre-eclampsia but not those with gestational hypertension. 
Both maternal serum and placental concentrations of inhibin A and 
activin A were significantly higher in pre-eclampsia compared with levels in 
gestational hypertension, which in turn were higher than in normotensive 
controls. Alpha methyldopa therapy was associated with reduced serum and 
placental concentrations of inhibin A and activin A in pre-eclampsia but not in 
gestational hypertension. 
Arterial stiffness is increased in women with gestational hypertension 
compared with normotensive pregnant women, but increased significantly 
more in women with pre-eclampsia. In pre-eclampsia, but not in gestational 
hypertension, arterial stiffness is improved by treatment with alpha 
methyldopa. 
Prior to treatment, uterine artery indices of resistance were higher in 
women with pre-eclampsia compared with women with gestational 
hypertension or controls. There was no significant difference in resistance 
between gestational hypertension and controls. Treatment with alpha 
methyldopa did not significantly affect these indices in either pre-eclampsia or 
gestational hypertension. 
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We have established the normal ranges for pulse wave analysis 
parameters in normal pregnancy. There were no significant differences in 
these parameters between the two main ethnic groups in our population, 
namely Afrocaribbean and Caucasian. Arterial stiffness was significantly lower 
in pregnant compared with non-pregnant women. In normal pregnancy, aortic 
stiffness varies throughout pregnancy, reaching its nadir in the second 






The aim of this thesis was to investigate the effect of antihypertensive therapy 
on vascular and placental function in hypertensive disorders in pregnancy. 
The null hypothesis was that antihypertensive therapy with alpha methyldopa 
would not have any significant effect on vascular function or placental markers 
in hypertensive disorders in pregnancy. 
We found that therapy with methyldopa significantly reduced arterial 
stiffness (as measured by pulse wave analysis) and maternal serum and 
placental markers (sFlt-1, soluble endoglin, inhibin A and activin A) in pre- 
eclampsia, but not in gestational hypertension, thereby disproving the null 
hypothesis. 
Our findings suggest that, within 48 hours of commencing treatment in 
women with pre-eclampsia, alpha-methyldopa reduces placental production of 
sFItl, soluble endoglin, inhibin A and activin A, leading to a reduction in 
circulating levels; this has a beneficial effect on vascular endothelium and/or 
vascular wall, leading to a reduction in arterial stiffness. 
We confirmed that, prior to treatment, levels of sFlt-1 and soluble 
endoglin in both serum and placenta are increased in women with gestational 
hypertension but increased significantly more in women with pre-eclampsia. 
The same is true of serum and placental inhibin A and activin A. 
Antihypertensive treatment with alpha methyldopa is associated with a 
significant fall in both serum and placental concentrations of these four 
markers in women with pre-eclampsia, but not in gestational hypertension. 
These findings suggest that, in pre-eclampsia, alpha methyldopa may have a 
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direct effect on placental synthesis and/or secretory functions, leading to a 
reduction in circulating concentrations in maternal serum, and that this effect 
may not be simply the result of a reduction in maternal blood pressure and /or 
a change in utero-placental blood flow. As discussed in section 3.2.2, the 
inhibition of sFlt-1 by methyldopa may be mediated through the inhibition of 
adenylyl cyclase, leading to decreased production of cyclic AMP. Inhibition of 
cyclic AMP production may also be the mechanism by which alpha- 
methyldopa leads to reduced placental production of inhibin A and activin A 
(section 3.3.2). Alternatively, methyldopa may inhibit cytokine activity or 
release in trophoblasts which may in turn lead to a reduction in inhibin A and 
activin A secretion. 
The fact that changes in serum and placental concentrations of these 
four markers mirror each other, both before and after antihypertensive 
treatment, supports the hypothesis that the placenta is their primary source. 
We examined the possibility that the apparent difference in effect of 
methyldopa on these markers in pre-eclampsia and gestational hypertension 
was simply due to the fact that marker levels prior to treatment were higher in 
pre-eclampsia, so that a similar proportional change would be more likely to 
result in a statistically significant P value. However, this was not the case: the 
proportional change following treatment in women with pre-eclampsia was 
significantly greater than the proportional change in women with gestational 
hypertension. 
Marker levels were significantly higher in early onset compared with late 
onset, and in severe compared with mild pre-eclampsia. However, the 
improvement in marker levels in these groups before and after treatment was 
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similar; the difference was only a question of degree. It has been suggested 
that severe early onset pre-eclampsia might represent a different disease 
entity to the late onset (and usually milder) form. 390 However, our data 
suggest that severe and/or early onset pre-eclampsia is just a more severe 
form of the same disease process. 
We confirmed that arterial stiffness is increased in gestational 
hypertension but increased even more in women with pre-eclampsia. We 
showed for the first time that, in women with pre-eclampsia but not in women 
with gestational hypertension, methyldopa brings about a significant 
improvement in arterial stiffness. 
Arterial stiffness as measured by pulse wave analysis was significantly 
reduced following treatment in women with pre-eclampsia, but did not return 
to the same level as normotensive controls. This was in spite of adequate 
control of blood pressure, implying that the improvement in arterial stiffness 
was not due to a fall in blood pressure alone. This suggests that methyldopa 
also has an effect on maternal blood vessels, either improving vessel wall 
compliance or endothelial dysfunction. These benefits may be due to a direct 
effect on the vessel wall. Alternatively, they may be mediated through falls in 
the circulating maternal levels of sFltl, soluble endoglin, inhibin A or activin A; 
our work shows that changes in the levels of these markers in pre-eclampsia 
and gestational hypertension mirror the changes in arterial stiffness before 
and after treatment with methyldopa. Because these changes take place over 
a relatively short space of time, it is tempting to speculate that the effect on 
vascular endothelium or vascular wall is a functional rather than a structural 
change. 
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In our study, methyldopa therapy had no significant effect on uterine 
artery Doppler indices in either pre-eclampsia or gestational hypertension. 
This is perhaps surprising, given that this drug has been shown to reduce 
vasospasm in other (maternal) arteries in women with pre-eclampsia. It may 
be that the increased resistance found in the uterine arteries of women with 
pre-eclampsia is not so much due to vasospasm as to the earlier failure of 
adequate trophoblastic invasion, thus impairing the development of the low 
resistance system usually found in pregnancy. The fact that methyldopa did 
not significantly affect Doppler indices suggests that the fall in placental levels 
of sFIt1, soluble endoglin, inhibin A and activin A was not due to an increase 
in uteroplacental perfusion. This supports the hypothesis that methyldopa has 
a direct effect on placental production and/or secretion of these markers. 
The fact that maternal serum and placental markers, and arterial 
stiffness, were affected in women with pre-eclampsia but not in women with 
gestational hypertension, suggests that these represent two different 
pathophysiological entities. 
We used multiple tools to study the effect of antihypertensive therapy, 
including anti-angiogenic and pro-angiogenic markers, inhibin A, activin A, 
uterine artery Doppler and pulse wave analysis. Some of these markers have 
previously been the subject of intensive research, while pulse wave analysis 
is considered novel in this field. 
We studied a group of women who developed non-proteinuric 
hypertension as well as a group with pre-eclampsia. This added to our 
understanding of the differences between these two conditions; the two 
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groups responded differently to antihypertensive treatment despite a similar 
reduction in blood pressure. 
We measured marker levels within 48 hours after the commencement of 
methyldopa therapy. Maximal anti hypertensive effect from methyldopa is not 
gained until at least 48 hours following commencement of treatment, so it is 
possible that, with longer duration of treatment, a greater effect on markers 
levels might have been observed. 
From the scientific point of view, it would have been interesting to 
include a control group of women with pre-eclampsia in whom treatment was 
indicated but withheld, and another group of normotensive women who did, 
but this was not considered ethically acceptable. However, it would be 
reasonable to expect that in such a control group, levels of maternal serum 
markers would either stay the same or increase still further over a 48-hour 
period. In contrast, in women treated with methyldopa over this time period, 
there was a significant fall in serum markers, suggesting that this is a genuine 
effect. 
I believe that my work in preparing this thesis has greatly enhanced my 
practical and theoretical knowledge, specifically in the area of hypertensive 
disorders in pregnancy, but more broadly in research methodology in general. 
I now realise that measurement of peripheral blood pressure is a crude 
indicator of the changes taking place in the cardiovascular system, and that 
there is more information in the arterial pulse wave which should be 
appreciated. In the long-term, markers of the vascular changes taking place at 
the molecular level are likely to prove the best tools for understanding and 
managing these disorders. 
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I now feel that we should question our concept that antihypertensive 
therapy leads only to reduction in blood pressure and appreciate that it may 
potentially affect the pathophysiological changes in pre-eclampsia. This effect 
may vary according to the individual antihypertensive drug. 
On a practical level, I have learned from scratch how to set up, run and 
complete a complex study, from devising a protocol and obtaining ethics 
approval, to recruiting and studying women, to processing serum and 
placental samples in the laboratory, to analysing, presenting and publishing 
my findings. My skills in ultrasound scanning and pulse wave analysis have 
also been honed along the way. I feel certain that all of this will benefit me in 
my future career in clinical and academic medicine. 
In women with pre-eclampsia, levels of these four markers fell after 
treatment with methyldopa but, in spite of normalisation of blood pressure, 
levels did not fall to those of normotensive controls. It would be interesting to 
investigate whether more aggressive treatment could restore these levels to 
normal, perhaps representing better control of the disease process. A 
potential disadvantage of this approach is the possibility that more aggressive 
antihypertensive treatment might lead to lower blood pressure and impairment 
of uteroplacental perfusion. Doppler examination in this study suggests that 
the levels of treatment currently used do not produce any such impairment. 
It would also be potentially valuable to explore the effect of other 
antihypertensive medications on these maternal serum markers. Other 
antihypertensives which produce similar effects on blood pressure might have 
a more beneficial effect on these markers, possibly representing better control 
of the underlying disease. 
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In the non-pregnant population, it has been shown that different 
antihypertensive drugs, while bringing about a similar reduction in peripheral 
blood pressure, result in different changes in central (aortic) haemodynamics 
as measured by arterial pulse wave analysis and this translates into better 
long-term clinical outcomes. Such studies have led to significant changes in 
the guidelines for managing hypertension in the non-pregnant population. Our 
findings suggest that similar studies using pulse wave analysis to assess the 
central effects of the different anti hypertensives used in pregnancy may be 
valuable. 
I believe that this work has disproved the null hypothesis that 
antihypertensive therapy with alpha methyldopa does not have any significant 
effect on vascular function or placental markers in hypertensive disorders in 
pregnancy, specifically in the case of pre-eclampsia. 
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Appendix I 
Inhibin A Assay Diluent 
Reagents: 
" 10% BSA (protease free) 
" 5% mouse serum 
" 5% Triton X-100 
9 0.15 M NaCl 
" 0.1% Sodium Azide 
" 0.1 M Tris HCI buffer (pH 7.5) 
To make up 500 mis: 
" 50g BSA 
9 25 mis mouse serum 
" 25 mis Triton X-100 
" 4.375 g NaCl 
" 0.5 g Sodium Azide 
" 45 mis 1M Tris made up to 450 mis with distilled water 
Mix well for 30-60 minutes and filter diluent through cotton wool. 
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Appendix 2 
ELISA Wash Buffer (X 20 Stock) 
Reagents: 
"1M Tris base - 0.05M (x 20) 
9 3M NaCI - 0.15M (x 20) 
9 1% Sodium Azide - 0.05% (x 20) 
" Tween20 
0 
To make up 2.5 litres stock buffer. 
9 Tris base - 302.75 g 
" NaCl - 175.32 g 
" Sodium Azide - 25 g 
Dissolve in 2 litres of distilled H2O, neutralise pH using concentrated HCI to 
pH 7.5. 
Make up volume to 2.5 litres using distilled water. 
Preparation of 10 litres normal wash buffer from stock: 
For 10 litres: 
" 500 mis stock buffer (pH 7.5) 
" 9.5 litres distilled water. 
.5 mis Tween20. 
Stir well for 30 minutes and store at room temperature. 
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Appendix 3 
ELISA manual wash buffer 
Reagents: 
" 0.05M Tris HCI buffer 
9 0.15M NaCl 
To make up 500 ml: 
" 25 mis of 1M Tris HCI buffer (pH 7.5) 
" 475 mis distilled water 
9 4.4 g NaCl 
Mix well and store at 4 °C. 
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Appendix 4 
ELISA Stop Solution 
Reagents: 
" Concentrated sulphuric acid (H2SO4) 
" Distilled water 
To make 1 Molar H2S04: 
Under the fume hood take 946.74 mis distilled water in a glass bottle and 
measure 53.26 mis concentrated H2SO4 with a glass pipette. Add the acid to 
the water and mix well. 
To make 500 mis 0.3 Molar H2S04-ELISA Stop solution: 
Add 150.15 mis of 1M H2SO4 to 349.85 mis distilled water. 
Mix well and store at room temperature. 
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Appendix 5 
Sample buffer for Activin A ELISA 
Reagents: 
" Phosphate Buffered Saline 
9 10% BSA (protease free) 
9 0.1% Sodium Azide 
To make up 100 mis: 
" Dissolve 1 PBS tablet in 100 mis distilled water 
" 10 g BSA 
9 100 mg Sodium Azide. 
Mix well and store at 4 °C. 
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